model make data available researcher sustainable way, data sharing becomes part clinical research enterprise future. mission YODA Project increase access clinical research data, promote use generate new knowledge. Yale University Open Data Access (YODA) Projects mission advocate responsible sharing clinical research data, open science, research transparency. Project committed supporting research focused improving health patient informing science public health. YODA Project improve feedback. Please share comment ideas. YODA Project seek mutually beneficial partnership Data Partners, promoting independence, responsible conduct research, good stewardship data, generation knowledge best interest society. participate, Data Partner must transfer full jurisdiction data access YODA Project. YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries right search truth implies also duty; one must conceal part one ha recognized true. Albert Einstein Mission Yale University Open Data Access (YODA) Projects mission advocate responsible sharing clinical research data, open science, research transparency. Project committed supporting research focused improving health patient informing science public health. YODA Project improve feedback. Please share comment ideas. Model YODA Project seek mutually beneficial partnership Data Partners, promoting independence, responsible conduct research, good stewardship data, generation knowledge best interest society. participate, Data Partner must transfer full jurisdiction data access YODA Project. Request Data ready request data? date, 459 trial identified available. YODA Project Data Partners continue identify add more. 115 Publications! Featured Articles Articles making use data shared YODA Project. Scroll featured article *115 publication 104 research projects. Hopkins AM, Modi ND, Abuhelwa AY, Kichenadasse G, Kuderer NM, Lyman GH, Wiese MD, McKinnon RA, Rockhold FW, Mann A, Rowland A, Sorich MJ. Heterogeneity Utility Pharmaceutical Company Sharing Individual-Participant Data Packages. JAMA Oncol. 2023 Dec 1;9(12):1621-1626. doi: 10.1001/jamaoncol.2023.3996. PMID: 37796495; PMCID: PMC10557028. Almansour SA, Alqudah MAY, Abuhelwa Z, Al-Shamsi HO, Semreen MH, Bustanji Y, Soare NC, McKinnon RA, Sorich MJ, Hopkins AM, Abuhelwa AY. Association proton pump inhibitor use survival adverse effect outcome patient multiple myeloma: pooled analysis three clinical trials. Sci Rep. 2024 Jan 5;14(1):591. doi: 10.1038/s41598-023-48640-1. PMID: 38182614; PMCID: PMC10770405. Chen R, Tie Y, Huang Y, Zhang X, Zeng Z, Chen M, Li L, Zhang S. Rapidly achieving clinical remission ulcerative colitis indicates better endoscopic histological outcomes. United European Gastroenterol J. 2023 Dec 30. doi: 10.1002/ueg2.12515. Epub ahead print. PMID: 38159047. Chekroud AM, Hawrilenko M, Loho H, Bondar J, Gueorguieva R, Hasan A, Kambeitz J, Corlett PR, Koutsouleris N, Krumholz HM, Krystal JH, Paulus M. Illusory generalizability clinical prediction models. Science. 2024 Jan 12;383(6679):164-167. doi: 10.1126/science.adg8538. Epub 2024 Jan 11. PMID: 38207039. Harton J, Segal B, Mamtani R, Mitra N, Hubbard RA. Combining real-world randomized control trial data using data-adaptive weighting via on-trial score. Statistics Biopharmaceutical Research. 2022;15(2):40820. doi:10.1080/19466315.2022.2071982 Fukuokaya W, Mori K, Yanagisawa T, Akazawa K, Shimomura T, Kimura T. Association concomitant proton pump inhibitor use survival patient metastatic prostate cancer receiving abiraterone acetate: post-hoc analysis pooled data three randomized controlled trials. Prostate Cancer Prostatic Dis. 2023 Jul 18. doi: 10.1038/s41391-023-00695-x. Epub ahead print. PMID: 37464102. Ruzich E, Ritchie J, Ginchereau Sowell F, et al. powerful partnership: researcher patient working together develop patient-facing summary clinical trial outcome data. Journal American Medical Informatics Association : JAMIA. 2023 Jun:ocad099. DOI: 10.1093/jamia/ocad099. PMID: 37341698. Samara MT, Levine SZ, Leucht S. Linkage Young Mania Rating Scale Clinical Global Impression Scale Enhance Utility Clinical Practice Research Trials. Pharmacopsychiatry. 2023 Jan;56(1):18-24. doi: 10.1055/a-1841-6672. Epub 2022 Jul 27. PMID: 35896419. Nikolin S, Rodgers A, Schwaab A, Bahji A, Zarate C Jr, Vazquez G, Loo C. Ketamine treatment major depression: systematic review meta-analysis. EClinicalMedicine. 2023 Aug 3;62:102127. doi: 10.1016/j.eclinm.2023.102127. PMID: 37593223; PMCID: PMC10430179. Chen R, Li L, Tie Y, Chen M, Zhang S. Trajectory fecal lactoferrin predicting prognosis ulcerative colitis. Precis Clin Med. 2023 Sep 5;6(3):pbad022. doi: 10.1093/pcmedi/pbad022. PMID: 38025971; PMCID: PMC10680133. website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries right search truth implies also duty; one must conceal part one ha recognized true. Albert Einstein Mission Yale University Open Data Access (YODA) Projects mission advocate responsible sharing clinical research data, open science, research transparency. Project committed supporting research focused improving health patient informing science public health. YODA Project improve feedback. Please share comment ideas. Model YODA Project seek mutually beneficial partnership Data Partners, promoting independence, responsible conduct research, good stewardship data, generation knowledge best interest society. participate, Data Partner must transfer full jurisdiction data access YODA Project. Request Data ready request data? date, 459 trial identified available. YODA Project Data Partners continue identify add more. 115 Publications! Featured Articles Articles making use data shared YODA Project. Scroll featured article *115 publication 104 research projects. Hopkins AM, Modi ND, Abuhelwa AY, Kichenadasse G, Kuderer NM, Lyman GH, Wiese MD, McKinnon RA, Rockhold FW, Mann A, Rowland A, Sorich MJ. Heterogeneity Utility Pharmaceutical Company Sharing Individual-Participant Data Packages. JAMA Oncol. 2023 Dec 1;9(12):1621-1626. doi: 10.1001/jamaoncol.2023.3996. PMID: 37796495; PMCID: PMC10557028. Almansour SA, Alqudah MAY, Abuhelwa Z, Al-Shamsi HO, Semreen MH, Bustanji Y, Soare NC, McKinnon RA, Sorich MJ, Hopkins AM, Abuhelwa AY. Association proton pump inhibitor use survival adverse effect outcome patient multiple myeloma: pooled analysis three clinical trials. Sci Rep. 2024 Jan 5;14(1):591. doi: 10.1038/s41598-023-48640-1. PMID: 38182614; PMCID: PMC10770405. Chen R, Tie Y, Huang Y, Zhang X, Zeng Z, Chen M, Li L, Zhang S. Rapidly achieving clinical remission ulcerative colitis indicates better endoscopic histological outcomes. United European Gastroenterol J. 2023 Dec 30. doi: 10.1002/ueg2.12515. Epub ahead print. PMID: 38159047. Chekroud AM, Hawrilenko M, Loho H, Bondar J, Gueorguieva R, Hasan A, Kambeitz J, Corlett PR, Koutsouleris N, Krumholz HM, Krystal JH, Paulus M. Illusory generalizability clinical prediction models. Science. 2024 Jan 12;383(6679):164-167. doi: 10.1126/science.adg8538. Epub 2024 Jan 11. PMID: 38207039. Harton J, Segal B, Mamtani R, Mitra N, Hubbard RA. Combining real-world randomized control trial data using data-adaptive weighting via on-trial score. Statistics Biopharmaceutical Research. 2022;15(2):40820. doi:10.1080/19466315.2022.2071982 Fukuokaya W, Mori K, Yanagisawa T, Akazawa K, Shimomura T, Kimura T. Association concomitant proton pump inhibitor use survival patient metastatic prostate cancer receiving abiraterone acetate: post-hoc analysis pooled data three randomized controlled trials. Prostate Cancer Prostatic Dis. 2023 Jul 18. doi: 10.1038/s41391-023-00695-x. Epub ahead print. PMID: 37464102. Ruzich E, Ritchie J, Ginchereau Sowell F, et al. powerful partnership: researcher patient working together develop patient-facing summary clinical trial outcome data. Journal American Medical Informatics Association : JAMIA. 2023 Jun:ocad099. DOI: 10.1093/jamia/ocad099. PMID: 37341698. Samara MT, Levine SZ, Leucht S. Linkage Young Mania Rating Scale Clinical Global Impression Scale Enhance Utility Clinical Practice Research Trials. Pharmacopsychiatry. 2023 Jan;56(1):18-24. doi: 10.1055/a-1841-6672. Epub 2022 Jul 27. PMID: 35896419. Nikolin S, Rodgers A, Schwaab A, Bahji A, Zarate C Jr, Vazquez G, Loo C. Ketamine treatment major depression: systematic review meta-analysis. EClinicalMedicine. 2023 Aug 3;62:102127. doi: 10.1016/j.eclinm.2023.102127. PMID: 37593223; PMCID: PMC10430179. Chen R, Li L, Tie Y, Chen M, Zhang S. Trajectory fecal lactoferrin predicting prognosis ulcerative colitis. Precis Clin Med. 2023 Sep 5;6(3):pbad022. doi: 10.1093/pcmedi/pbad022. PMID: 38025971; PMCID: PMC10680133. website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Welcome YODA Project Remarkable quantity data generated clinical research, much never published disseminated, limiting integration current knowledge treatment efficacy safety. data could used replicate extend previous research findings; others could combined additional data enable researcher analyze result larger number patients. used address secondary research question generate new knowledge. challenge facing clinical research enterprise ha develop sustainable method qualified researcher clinician access data utilize advance science. Sharing clinical data already existence efficient use collective scientific resource maximizes valuable contribution volunteer participate research. Yale University Open Data Access (YODA) Project theadvocates responsible sharing clinical research data. Project committed open science data transparency, support research attempting produce concrete benefit patients, medical community, society whole. experience input public stakeholders, YODA Project ha iteratively developed model make data available researcher sustainable way, data sharing becomes part clinical research enterprise future. mission YODA Project increase access clinical research data, promote use generate new knowledge. Dr. Harlan Krumholz open science YODA Project. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Policies & Procedures Guide External Investigator Access Clinical Trial Data Policy Guide External Investigator Access Clinical Trial Data Yale University Open Data Access (YODA) Project effort group academically-based clinical researcher promote facilitate sharing clinical trial data. set policies, represents refinement policy guided access data made available Medtronic, Inc., intended cover YODA Projects partnership Johnson & Johnson, also set standard relevant future effort similar aspirations. Importantly, YODA Project ha final decision-making right regarding policy and, extension, granting denial data requests, per contractual agreement YODA Project partners. serving role, YODA Projects goal enhance data availability transparency support strong scientific research aim advance scientific medical knowledge ultimate goal improving public health healthcare delivery. document outline YODA Projects policy guide decision-making related granting access data. YODA Project seek continually improve policy and, accordingly, may modify policy future. YODA Project? YODA Project effort group academically-based clinical researcher facilitate access participant-level clinical research data and/or comprehensive report clinical research, full Clinical Study Reports (CSRs), level detail customarily found journal publications, aim promoting scientific research may advance science lead improvement individual public health healthcare delivery. YODA Project guided following core principles, reflect overall mission project promote open science by: Promoting sharing clinical research data advance science improve public health healthcarePromoting responsible conduct researchEnsuring good stewardship clinical research dataProtecting right research participant Policy Scope:This data release policy applies request received YODA Project access clinical trial data held third party YODA Project ha agreement serve decision-making role regarding granting denial requests. policy address research proposal requirements, data receipt, data analysis, dissemination results. Specifically, policy guide procedure used make completed clinical trial data (including CSRs participant-level data) available external investigator independent scientific examination. policy doe apply request research partnership type data, biological, pharmacological, radiographic data, beyond scope YODA Project. policy wa informed following: YODA Projects prior experience sharing Medtronics participant-level clinical trial data recombinant human bone morphogenetic protein-2 (rhBMP-2);Recommendations YODA Project Steering Committee, independent group leader field clinical research biomedical ethic convened YODA Project provide guidance;Recommendations experts, stakeholders, industry partners; andThe YODA Projects review literature policy body engaged clinical trial data sharing. Policy Statement:The YODA Project committed facilitating external access clinical trial data made available third party Data Partners promote research informs science public health. project doe support request use data non-scientific purposes, pursuit litigation commercial interests. YODA Project require requestors provide basic information Principal Investigator, Key Personnel, project Research Proposal, including scientific abstract research methods. Registration information used YODA Project track use data, promote responsible conduct research, publicly post information ha obtained access data scientific purpose. YODA Project review proposal ensure proposal ha scientific merit, 1) scientific purpose clearly described; 2) data requested used create materially enhance generalizable scientific and/or medical knowledge inform science public health; 3) proposed research reasonably addressed using requested data. Scientific review peer expert and/or member YODA Project Steering Committee may solicited YODA Project unable verify scientific merit proposal. YODA Project request Due Diligence Assessment Data Partner requested data currently available secure data sharing platform order determine ability make data available shared externally, including estimation resource would required. Requestors may similarly request Assessment data yet available prior preparing full proposal. Requests include independent funding considered, neither expected required. YODA Project willall request registration information, including Research Proposal analysis plan, summary Data Partner Due Diligence Assessment, scientific review peer expert YODA Project Steering Committee, YODA Projects decision grant deny data access. access denied, public report detailing reason(s) provided. Public posting intended promote transparency clinical research public accountability YODA Project data release process. Prior receiving data access, requestors asked sign Data Use Agreement (DUA). DUA explicitly state access data used create materially enhance generalizable scientific knowledge finding derived analysis initially publicly disseminated peer-reviewed biomedical literature scientific meetings, exception unexpected serious safety finding (which reported Data Partner immediately evaluation reporting appropriate health regulatory authorities). addition, requestors must certify use enable others use data commercial purpose pursuit litigation. Released data include data relevant Research Proposal available, including collected participant-level data set (appropriately de-identified per current regional standard protect patient privacy), annotated case report forms, data set specifications, protocol amendments, reporting analysis plans, complete CSRs. Depending Data Partner, data made available either via password-protected personalized account secure data sharing platform secure electronic data transfer system. details, including key definitions, found our. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Development Policies & Procedures Yale University Open Data Access (YODA) Project requested public comment policy procedure guide process used make clinical trial data available, including Clinical Study Reports participant-level data. comment available below. policy procedure informed following: YODA Projects prior experience sharing Medtronics participant-level clinical trial data recombinant human bone morphogenetic protein-2 (rhBMP-2);Recommendations YODA Project Steering Committee, independent group leader field clinical research biomedical ethic convened YODA Project provide guidance;Recommendations experts, stakeholders, industry partners; andThe YODA Projects review literature policy body engaged clinical trial data sharing. public comment taken consideration, incorporated discretion YODA Project. YODA Project seek continually improve policy and, accordingly, may modify policy future. information found via link below: Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Due Diligence Assessment Requests data already available secure data sharing platform undergo Due Diligence Assessment Data Partner. primary purpose Due Diligence Assessment Data Partner provide YODA Project assessment ability make data available shared externally, reviewing Data Partners legal regulatory consideration order determine legal ethical right make data available external investigator scientific purposes. However, Due Diligence Assessment also include estimation resource would required make data available external requestors, time effort required de-identify data compliance current regional standard protect patient privacy prepare necessary accompanying documentation, providing understanding technical consideration release older clinical trial data exist easily shareable format. rationale collecting information broadly inform field estimate resource required Data Partners make data available. Due Diligence Assessment also include determination whether researchers, either internally employed externally affiliated Data Partner, engaged similar research studies. rationale making determination external requestors made aware similar ongoing research effort (so misunderstanding generation research ideas), well foster collaborations. Requests data already listed available YODA Project website undergo Due Diligence Assessment Data Partner purpose only. Lastly, Due Diligence Assessment ass whether proposed research reasonably addressed using requested data, including whether variable needed proposed analysis included requested data whether research question addressed using summary-level data. information, refer to(Section 4) theform used Johnson & Johnson. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Data Use Agreement signed Data Use Agreement (DUA) required data access YODA Project. DUAs specific Data Partner, detail specific requirement around following: Data access Data use Reporting unexpected/serious safety finding Redistribution data dissemination result such, DUA specific data requested carefully reviewed prior submitting data request. DUA specific YODA Project Data Partner available below. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Data Expiration data regardless Data Partner expiration date one year signing DUA, renewed additional time one-year period project ongoing. complete projects, investigator retain right access data additional five year express purpose verification investigator publication respond inquiry regarding publication. data cannot used additional analysis. additional analysis require new application data access YODA Project. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Project Leadership Principal Investigator Professor Medicine (General Medicine) Public Health (Health Policy) Professor Medicine (General Medicine) Epidemiology (Chronic Diseases) Associate Professor Medicine (Cardiology) Senior Lecturer, Institute Applied Health Sciences, University Birmingham, UK Assistant Professor Epidemiology, Emory University Senior Project Manager Research Associate II Postgraduate Associate Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Steering Committee Steering Committee provides guidance YODA Project, specifically reference developing process making clinical trial data available external investigators, well process reviewing request data. Steering Committee comprised leader field clinical research biomedical ethics. Ezekiel J. Emanuel, MD, PhD General Steering Committee Chair(2011-present) Vice Provost Global Initiatives, Diane v.S. Levy Robert M. Levy University Professor, Chair Department Medical Ethics Health Policy, University Pennsylvania James (Jim) D. Neaton, PhD(2011-present) Professor Biostatistics, University Minnesota School Public Health Bruce M. Psaty, MD, PhD(2011-present) Professor Medicine, Epidemiology, Health Services Co-Director Cardiovascular Health Research Unit, University Washington Rita Redberg, MD, MSc(2011-present) Cardiologist Professor Medicine, University California, San Francisco (UCSF), Core Faculty, Philip R. Lee Institute Health Policy Studies, Chief Editor, JAMA Internal Medicine Dennis Thompson, PhD(2011-present) Alfred North Whitehead Professor Political Philosophy Emeritus, Harvard University, Founding Director Edmond J. Safra Center Ethics Deborah Zarin, MD(2011-present) Director, ClinicalTrials.gov, National Library Medicine YODA Project would like acknowledge following additional individual contribution endeavor: Kevin J. Bozic, MD, MBA- Clinical Advisory Committee Chair (2011-2013)Michael B. Bracken, MPH, PhD- Project Consultant (2011)Allan Coukell, BScPharm- General Steering Committee Member (2011-2016)Ralph I. Horwitz, MD, MACP- General Steering Committee Member (2011-2013)Haiqun Lin, MD, PhD- Project Consultant (2011-2018)Mark Litwin, MD, MPH- Clinical Steering Committee Member (2011-2013)Sohail K. Mirza, MD, MPH- Clinical Steering Committee Member (2011-2013)Sharon-Lise Normand, PhD- Project Consultant (2011)Regis J. OKeefe, MD, PhD- Clinical Steering Committee Member (2011-2013)Steven D. Pearson, MD, MSc- General Steering Committee Member (2011-2013)Daniel K. Resnick, MD- Clinical Steering Committee Member (2011-2013)Marc F. Swiontkowski, MD- Clinical Steering Committee Member (2011-2013) Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Roles & Responsibilities YODA Project DoesThe YODA Project effort group academically-based clinical researcher facilitate access participant-level clinical research data and/or comprehensive report clinical research, full Clinical Study Reports [CSRs], aim promoting scientific research may advance science lead improvement individual public health healthcare delivery. YODA Project ha served trusted third party variety collaborative effort make scientific data broadly available researcher betterment patients, scientific research, society. Ongoing project include conducting independent review request access pharmaceutical medical device company data could enable new scientific discoveries. expectation open science research transparency expands, YODA Project continues evolve leader responsible data access maintaining touchstone core values. YODA Project DoThe YODA Project ha generated owns data made available open science projects. impartial perspective enables YODA Project promote principle manner uninfluenced individual stakeholder bias work mediator, facilitator, activist responsible data sharing. Clear role responsibility delineated YODA Project Data Partners. YODA Project committed to: Facilitating request access clinical trial dataConducting independent, third-party review requestsProviding access data following approval data requestsEnsuring data shared YODA Project used generate knowledge inform science public health Data Partners committed to: Making possible clinical trial data available external investigatorsHandling operational/technical aspect data accessPosting completed trial result ClinicalTrials.gov soon available Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Partnering YODA Project Data sharing data transparency becoming new standard pharmaceutical medical device science. data sharing method continue expand, YODA Project strives innovative leader set standard field. YODA Project approach data sharing unique following ways: YODA Project independent, academic organization collaborating Data Partners, removing perception influence access Data Partners given YODA Project full jurisdiction make decision regarding data access YODA Project review request associated registration material ensure required information completely submitted, committed facilitating external access data scientific purpose inquiry related partnering YODA Project share clinical trial data, please contact. Data PartnersThe Yale University Open Data Access (YODA) Project currently collaborating following Data Partners facilitate access clinical trial program data: Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Johnson & Johnson Available Data Johnson & Johnson currently making clinical trial data pharmaceutical, medical device, consumer product available. Johnson & Johnson ha adopted policy foster sharing clinical trial data, including recently completed well older trials. trial listed available, Johnson & Johnson confirms location data electronic format, well agreement collaboration partner ensure trial listed shared. sharing site confirmed meet criteria. YODA Project Johnson & Johnson continuously add list, additional trial identified meet criteria. case clinical trial meet criteria, disclosure study data sole discretion Data Partner. question availability trial currently included trial list, please. Pharmaceutical Data Researchers may submit request full CSRs and/or de-identified participant-level data pharmaceutical Phase II-IV clinical trial which: Janssen Pharmaceutical Companies Johnson & Johnson market authorization holder; product relevant indication studied approved regulator US EU; study ha completed 18 months. OPTICS Trial Bundle OPTICS (Open Translational Science Schizophrenia) wa project designed provide forum true translational science based Janssen clinical trial publicly available data related observational study trial schizophrenia. goal wa demonstrate value open-science approach fostering collaboration leading insight disease therapeutic safety efficacy. OPTICS Statement Janssen Open Translational Science Schizophrenia (OPTICS) Project wa launched Janssen Research & Development, LLC, part Janssen Pharmaceutical Companies Johnson & Johnson, group leading research organization including National Institutes Health, Yale University School Medicine, Rutgers University, Harvard T.H. Chan School Public Health. aim project wa create forum collaborative analysis Janssens schizophrenia clinical trial data along publicly available schizophrenia data NIH. ultimate goal wa create new open science model conducting research. OPTICS Project wa one part larger effort Janssen Johnson & Johnson research company share clinical trial data enhance public health advance science medicine. end, intellectual property generated OPTICS Project wa dedicated public free use. information please visit theand the. OPTICS Project ha concluded, available. OPTICS data available YODA Project included17 paliperidone clinical trialsconducted Janssen. Medical Device Data Researchers may submit request full CSRs and/or de-identified participant-level data (as defined FDAAA) medical device trial which: member company Johnson & Johnson Medical Devices Companies market authorization holder; product relevant indication studied approved regulator US EU 2014 later; study wa initiated 2007 later; study ha completed 18 months. Consumer Data Researchers may submit request full CSRs and/or de-identified participant-level data interventional clinical study human consumer product regulated medicinals device which: member company Johnson & Johnson Consumer Inc. market authorization holder; product relevant indication studied initially authorized cleared US FDA EMA health authority anywhere world US FDA EMA authorization clearance required sought allow marketing region 2014 going forward; study ha completed 18 months. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Data Release Pilot Project Throughout development Policy Procedures Guide External Investigator Access Clinical Trial Data, YODA Project aimed support core principles. Many issue idea arose throughout development process required careful consideration YODA Project move forward. YODA Project spent past month determining best handle following question situations: fulfill data request requested data generated many year ago shareable data files? Much clinical trial data generated prior 1990 may available paper format readily accessible.There request data cannot legally ethically filled. instance, data request privacy confidentiality research participant data cannot protected clinical trial informed consent doe allow sharing de-identified data public health research educational purpose cannot filled. Additionally, data request compound ha obtained ha developed collaboration external partner require agreement data sharing involved partner request approved.How much time effort required appropriate data de-identification per current regional standard protect patient privacy well preparation necessary accompanying documentation data made available? YODA Project implemented staged approach data access better understand time, effort data format necessary release clinical trial data. data release pilot project included Due Diligence Assessment Janssen Pharmaceuticals ass following: ability make data available shared externally, including providing understanding technical consideration release older clinical trial data exist easily shareable formatThe informed consent documentation clinical trial interest ensure right privacy research participant upheldThe time effort required appropriate data de-identification per current regional standard protect patient privacy well preparation necessary accompanying documentation result pilot project helped inform improve YODA Project data release process. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Medtronic Overview YODA Project seek address problem unpublished selectively published clinical trial research. Medtronic wa first company contract YODA Project allow access clinical trial data independent reanalysis, tremendous step forward emerging era open science. part initiative, YODA Project first contracted two independent research group competitively selected review meta-analyze clinical study Medtronics rhBMP-2. Oregon Evidence-based Practice Center Oregon Health & Science University (OHSU) Portland, Oregon, Centre Reviews Dissemination University York, United Kingdom, selected. information outstanding research group found. publication independent, peer-reviewed review meta-analyses, comprehensive report theAnnals Internal Medicine, Medtronics rhBMP-2 clinical trial data made available investigator wished pursue scientific research, either address unanswered question reproduce work conducted OHSU York. data available investigator request June 2013-June 2015. initiative wa important step toward open science, whereby industry, investigators, regulator pursue transparent collaborative pathway clinical trial research, ensuring patient physician best possible understanding medical product effectiveness safety. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Medtronic Systematic Reviews Overview Yale University contracted two independent research group November 2011 perform rigorous systematic review evidence synthesis determine safety effectiveness rhBMP-2. competitive open process, Oregon Health & Science University (OHSU) University York selected. OHSU University York completed independent review entire body scientific evidence regarding safety effectiveness recombinant human bone morphogenetic protein-2 (rhBMP-2). team full access Medtronics clinical trial, post-marketing safety data rhBMP-2. OHSU University York independently developed final report based analysis rhBMP-2 data (links report available below). report formally reviewed expert member YODA Project Steering Committees, including orthopedic surgeons, statisticians, expert clinical trial design analysis, well representative manufacturer rhBMP-2, Medtronic, Inc. center refined report based reviewer feedback peer-review comment made manuscripts. aim included following: Identify relevant studies, across user sponsor (i.e., Medtronic sponsored others).Determine question addressed studies.Evaluate quality studies. Assess risk bias associated design, conduct, reporting clinical study, including identified via systematic review provided Medtronic, and, present, bias may affected assessment effectiveness harms.Assessment study design conduct include evaluation internal validity, method used ascertain outcome policy procedure data collection, well integrity case report form (CRF) adjudication.Assessment study reporting include selective publication selective reporting.Summary finding include:What conclusion drawn assessing full body data gap knowledge remain, taking account result evaluation quality risk biasAn assessment applicability studies.Conduct meta-analyses study identified via systematic review, appropriate using patient-level data, possible. appropriate, another approach summarizing data. analysis consider following:For effectiveness, meta-analysis consider patient-centered outcome (i.e., quality life functional status), well surrogate outcome (i.e., fusion determined radiography).For safety, meta-analysis include harm described Request Proposal. Research Groups Oregon Health Science UniversityPrincipal Investigator Rongwei (Rochelle) Fu, PhDAssociate ProfessorDepartment Public Health Preventive MedicineOregon Evidence-based Practice CenterOregon Health Science University (OHSU) University YorkPrincipal Investigator Professor Lesley StewartDirector, Centre Reviews DisseminationUniversity YorkUniversity York Call Evidence Results independent review rhBMP-2 published June 18, 2013 issue Annals Internal Medicine OHSU:University York: Full comprehensive report written review organization OHSU:University York: Commentaries Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Approved Requests Use Medtronic Data Date Data Request Approved Principal Investigator Institution Name Project Protocol Publications October 10, 2013 Amber Laurie, MS Rochelle Fu, PhD Oregon Health Science University Meta-analysis influence patient characteristic effectiveness harm recombinant human bone morphogenetic protein-2 (rhBMP-2) lumbar spinal fusion . October 21, 2013 Alex Hodkinson, MSc University Liverpool Differences reporting harm data internal sponsored report versus corresponding published trial reports: Evaluating safety reporting rhBMP-2 17 Medtronic sponsored trial Data Transferred, Project Pursued, Certificate Data Destruction Received November 14, 2013 Andrew Indresano, MD University Wisconsin-Madison Re-evaluation Carcinogenicity rhBMP-2: Meta-Analysis Individual Participant-Level Data Yale University Open Data Access (YODA) Project Data Transferred, Project Pursued, Certificate Data Destruction Received January 16, 2014 Vikas Patel, MD University Colorado Meta-analysis Outcomes Complications Spinal Surgery Population Receiving Recombinant Human Bone Morphogenetic Protein-2 vs. Receiving Iliac Crest Bone Graft . Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Queen Mary University London Partnership Queen Mary University London March 2019-October 2021, Yale University Open Data Access (YODA) Project enabled scientist across world gain access clinical trial data supporting graded exercise therapy guided self-help trial (), compare efficacy safety guided graded exercise self-help (GES) added specialist medical care (SMC) SMC alone patient chronic fatigue syndrome (results published Lancet June 2017). partnership established independent process promoted open science goal leveraging prior research investment produce new knowledge. YODA Project performed independent scientific review investigator request participant-level data underlying GETSET trial. QMUL conferred YODA Project authority make decision release clinical trial data. allowed request clinical data fairly judged decided upon independent academic partner.No request received use GETSET data. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries SI-BONE Partnership SI-BONE, Inc. May 2016-April 2023, Yale University Open Data Access (YODA) Project enabled scientist across world gain access SI-BONEs key clinical study iFuse Implant System, minimally invasive surgical device indicated fusion certain disorder sacroiliac joint. partnership established independent process promoted open science goal leveraging prior research investment produce new knowledge. YODA Project performed independent scientific review investigator request SI-BONEs clinical study iFuse Implant System, including participant-level data. SI-BONE conferred YODA Project authority make decision release clinical trial data. allowed request clinical data fairly judged decided upon independent academic partner. SI-BONE shared data SIFI (Sacroiliac Joint Fusion iFuse Implant System) INSITE (Investigation Sacroiliac Fusion Treatment) studies. request received use SI-BONE data. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Publications & Presentations Publications Articles YODA Project Vazquez E, Gouraud H, Naudet F, Gross CP, Krumholz HM, Ross JS, Wallach JD..Clin Trials. 2021 Aug 18:17407745211038524. doi: 10.1177/17407745211038524 Ross JS, Waldstreicher J, Krumholz HM..STAT News. 2019. Ross JS, Waldstreicher J, Bamford S, Berlin JA, Childers K, Desai NR, Gamble G, Gross CP, Kuntz R, Lehman R, Lins P, Morris SA, Ritchie JD, Krumholz HM..Sci Data. 2018;5:180268. Wilcox MA, Savitz AJ, Addington AM, Gray GS, Guinan EC, Jackson JW, Lehner T, Normand SL, Ranu H, Senthil G, Spertus J, Valeri L, Ross JS..NPJ Schizophr. 2018;4(1):14. Low J, Ross JS, Ritchie JD, Gross CP, Lehman R, Lin H, Fu R, Stewart LA, Krumholz HM..Systematic Reviews. 2017;6:28. Krumholz HM, Waldstreicher J..NEJM. 2016;375:403-405. Ross JS, Addington AM, Senthil G, Lehner T, Wilcox MA.Psychiatric Times. 2016;33. Krumholz HM, Ross JS, Gross CP, Emanuel EJ, Hodshon B, Ritchie JD, Low JB, Lehman R. A.Ann Intern Med. 2013;158:910-911. Krumholz HM, Ross JS..JAMA. 2011;306:1593-1594. Articles Data Sharing Ross JS, Waldstreicher J, Krumholz HM. N Engl J Med. 2023 Nov 15. doi: 10.1056/NEJMp2308792. Epub ahead print. PMID: 37966303. Rowhani-Farid A, Grewal M, Solar S, Eghari A, Zhang A, Gross C, Krumholz H, Ross J. Sci Data. 2023:10;529. https://doi.org/10.1038/s41597-023-02436-0 Tannenbaum S, Ross JS, Krumholz HM, Desai NR, Ritchie JD, Lehman R, Gamble GM, Bachand J, Schroter S, Groves T, Gross CP..Ann Intern Med. [Epub ahead print 17 July 2018] doi: 10.7326/M18-0723. Dey P, Ross JS, Ritchie JD, Desai NR, Bhavnani SP, Krumholz HM..JACC. 2017;70:3018-3025. Angraal S, Ross JS, Desai N, Dhruva SS, Krumholz HM..JACC. 2017;70:1825-1826. Ross JS, Ritchie JD, Finn E, Desai NR, Lehman RL, Krumholz HM, Gross CP..BMJ Open. 2016;6:e012769. Ross JS..Systematic Reviews. 2016;5:159. Krumholz HM, Bourne PE, Kuntz RE, Paz HL, Terry SF, Waldstreicher J..JAMA. 2016;epub ahead print. Murugiah K, Ritchie JD, Desai NR, Ross JS, Krumholz HM..J Heart Assoc. 2016;5:e003307. Krumholz HM. . BMJ. 2015;350:h599. Rathi VK, Strait KM, Gross CP, Hrynaszkiewicz I, Joffe S, Krumholz HM, Dzara K, Ross JS..Trials.2014;15:384. Krumholz HM, Peterson ED..JAMA. 2014;312:1002-1003. Krumholz HM, Gross CP, Blount KL, Ritchie JD, Hodshon B, Lehman R, Ross JS..Circ Cardiovasc Qual Outcomes. 2014;7:499-504. Ross JS, Krumholz HM..JAMA. 2013;309:1355-1356. Ross JS, Krumholz HM.. Medical Writing. 2013;22:45-49. Rathi V, Dzara K, Gross CP, Hrynaszkiewicz I, Joffe S, Krumholz HM, Strait KM, Ross JS..BMJ. 2012;345:e7570. Krumholz HM. . Circ Cardiovasc Qual Outcomes. 2012;5:141-142. Ross JS, Lehman R, Gross CP. .Circ Cardiovasc Qual Outcomes. 2012;5:238-240. Krumholz HM. . Cardiology. 2012;41:9. Lehman R, Loder E..BMJ.2012;344:d8158. Articles Transparency Zou CX, Becker JE, Phillips AT, Garritano JM, Krumholz HM, Miller JE, Ross JS..Trials. 2018;19(1):581. Phillips AT, Desai NR, Krumholz HM, Zou CX, Miller JE, Ross JS..Trials. 2017;18:333. Krumholz HM, Kim J..Ann Intern Med. [Epub ahead print 4 April 2017] doi: 10.7326/M17-0743 Phillips AT, Rathi VK, Ross JS..JAMA Intern Med. 2016;176:551-552. Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, Murugiah K, Lu DY, Mittal A, Krumholz HM. . BMJ. 2016;352:i637. Gopal AD, Desai NR, Tse T, Ross JS..JAMA. 2015;313:1163-1165. Ross JS..JAMA Intern Med.2015;175:307. Lauer MS, Krumholz HM, Topol EJ.?Lancet.2015;386:2447-2449. Shaw DL, Ross JS..AMA Journal Ethics. 2015;17:1152-1159. Krumholz HM. . Circ Cardiovasc Qual Outcomes. 2015;8:00-00. Smithy JW, Downing NS, Ross JS..JAMA Intern Med. 2014;174:1518-1520. Lehman R..BMJ.2014;348:g3963. Becker JE, Krumholz HM, Ben-Josef G, Ross JS..JAMA. 2014;311:1063-1065. Ross JS, Mocanu M, Lampropulos JF, Tse T, Krumholz HM..JAMA Intern Med. 2013;173:825-828. Ross JS, Gross CP, Krumholz HM..Am J Public Health. 2012;102:72-80. Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM..BMJ. 2011;344:d7292. Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM..PLoS Med. 2009;6:e1000144. Krumholz HM.Registries selection bias: .Circ Cardiovasc Qual Outcomes. 2009;2:517-518. Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS..BMJ. 2020 Feb 5;368:l7078. Approved research proposal through. Krumholz HM.Circ Cardiovasc Qual Outcomes.2013;6:371-372. Presentations (Given Cary P. Gross, MD National Brain Tumor Society Research Roundtable, July 20, 2023) (Given Joseph S. Ross, MD, MHS, National Academies Challenges Way Forward Sharing Clinical Trial Data Workshop, November 18, 2019) (Given Joseph S. Ross, MD, MHS, Center Biomedical Research Transparency Summit, February 15, 2019) (Given Joseph S. Ross, MD, MHS, American Association Advancement Science Annual Meeting, February 15, 2019) (Given Joseph S. Ross, MD, MHS, Eighth International Congress Peer Review Scientific Publication, September 10, 2017) (Given Harlan M. Krumholz, MD, SM, Jeffrey M. Drazen, MD, Harvard Medical School Health Policy Bioethics Consortium Meeting, December 7, 2016) (Given Jessica Ritchie Klein, MPH, PMP, American Library Association Annual Meeting, June 27, 2016) (Given Joseph S. Ross, MD, MHS, Society Clinical Trials Annual Meeting, May 18, 2016) (Given Joseph S. Ross, MD, MHS, CBI Conference Clinical Data Disclosure Transparency, January 29, 2015) (Given Joseph S. Ross, MD, MHS, NPA FDA Taskforce Meeting, December 15, 2014) (Given Kevin Bozic, MD, American Academy Orthopaedic Surgeons (AAOS), Orthopaedic Research Society (ORS) Clinical Research Forum, February 6, 2012) (Given Harlan Krumholz, MD, American College Cardiology (ACC) Board Trustees Meeting, December 5, 2011) Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Announcements & Media Coverage YODA Project Announcements (Yale News, September 11, 2023) (Yale News, February 1, 2017) January 2017, YODA Project submitted January 2017, YODA Project submitted . (Yale News, August 3, 2016) (Yale News, May 12, 2016) April 2016, YODA Project submitted . November 2015, YODA Project submitted . March 2015, YODA Project submitted response . March 2015, YODA Project submitted response (Yale Daily News, January 28, 2015) (Yale News, January 14, 2015) (Yale News, October 20, 2014) Video: (YaleMedicine, March 13, 2014) (Yale News, January 30, 2014) (Yale News, June 17, 2013) (Yale News, December 5, 2011) January 2017, YODA Project submitted January 2017, YODA Project submitted . (Yale News, August 3, 2016) (Yale News, May 12, 2016) April 2016, YODA Project submitted . November 2015, YODA Project submitted . March 2015, YODA Project submitted response . March 2015, YODA Project submitted response (Yale Daily News, January 28, 2015) (Yale News, January 14, 2015) (Yale News, October 20, 2014) Video: (YaleMedicine, March 13, 2014) (Yale News, January 30, 2014) (Yale News, June 17, 2013) (Yale News, December 5, 2011) YODA Project Media Coverage (LinkedIn, September 12, 2023) (Future Privacy Forum, August 17, 2023) (The Scientist, December 3, 2018) James J. . (Pharma Tech Outlook CXO Insights, May 2017) (Clinical Informatics News, March 15, 2017) Wallach JD, Ross JS, Krumholz HM. . (BioMed Central Blog Network, February 15, 2017) (European Medicines Agency, October 20, 2016) (NEJM, August 3, 2016) (OPTICS, June 9, 2015) (Wall Street Journal, April 15, 2015) (Medical Device Diagnostic Industry, January 20, 2015) (Genetic Engineering Biotechnology News, January 15, 2015) (Vox, January 14, 2015) (Wall Street Journal, January 14, 2015) (Forbes, January 14, 2015) J&J becomes first devicemaker broadly share trial data subscription required (Modern Healthcare, January 14, 2015) (New York Times, January 14, 2015) (Vox, December 8, 2014) (Time, December 5, 2014) subscription required (Wall Street Journal, December 4, 2014) (AllTrials, November 20, 2014) (Wall Street Journal, November 19, 2014) (Scientific American, June 1, 2014) (The Scientist, May 1, 2014) (The Brown Daily Herald, April 7, 2014) (Nature Medicine, March 4, 2014) (chemistryworld, February 4, 2014) (New York Times, February 3, 2014) J&J allow access clinical research Yale open-data project subscription required (Modern Healthcare, January 30, 2014) (Johnson & Johnson, January 30, 2014) (Forbes, January 30, 2014) (Forbes, January 30, 2014) (Reuters, January 30, 2014) subscription required (Wall Street Journal, January 30, 2014) (Bloomberg, January 30, 2014) subscription required (Informa, January 30, 2014) (Xconomy, January 30, 2014) (Bloomberg Businessweek, June 18, 2013) (Minneapolis Star Tribune, June 18, 2013) (New York Times, June 17, 2013) (Wall Street Journal, June 17, 2013) (Reuters, June 17, 2013) (Medscape, June 17, 2013) (Stanford Medicine, June 17, 2013) (The Daily Edition AAOS Now, February 10, 2012) (MassDevice.com, November 14, 2011) (Minneapolis Star Tribune, November 14, 2011) (TheHeart.org, October 13, 2011) (BMJ Podcast, September 9, 2011) (BMJ, August 30, 2011) (Reuters, August 4, 2011) (New York Times, August 3, 2011) Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Relevant Literature YODA Project recommends following article interested learning data sharing field. Many article aided development YODA Project policy procedures. intended comprehensive list, additional resource added time. NIH Data Sharing Resources National Academy Medicine Greene SM, Ahmed M, Chua PS, Grossmann C, Editors. 2021. . Washington, DC: National Academy Medicine. National Academies Sciences, Engineering, Medicine.. Washington, DC: National Academies Press, 2020. Institute Medicine.Washington, DC, National Academies Press, 2015. Institute Medicine.Washington, DC, National Academies Press, 2014. Institute Medicine.Washington, DC, National Academies Press, 2005. Data Sharing Policies Progress Peterson ED, Rockhold FW..JAMA Cardiol. [Epub ahead print 2018 Jul 3] doi: 10.1001/jamacardio.2018.0129. Gibson CM..JAMA Cardiol. [Epub ahead print 2018 Jul 3] doi: 10.1001/jamacardio.2018.0130. Yancy CW, Harrington RA, Bonow RO..JAMA Cardiol. [Epub ahead print 2018 Jul 3]. doi: 10.1001/jamacardio.2018.1939. Zarin DA, Tse T, Williams RJ, Carr S..NEJM. 2016; 375:1998-2004. Economist.. October 6, 2015. University Bath. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF.JAMA.2015;313:1657-1665. Moorthy VS, Karam G, Vannice KS, Kieny M.PLOS Med.2015;12. Mitka M.JAMA.2015;313:881-882. Zarin DA, Tse T, Sheehan J.NEJM.2015;372:174-180. European Medicines Agency.October 2, 2014. Varnai P, Rentel MC, Simmonds P, Sharp TA, Mostert B, de Jongh, T.Study led Technopolis Group (UK), 2014. Bonini S, Eichler HG, Wathion N, Rasi G.NEJM.2014;371:2452-2455. Steinbrook R.JAMA Intern Med.2013;173:373-374. Doshi P, Goodman SN, Ioannidis JA.Trends Pharm Sci.2013;34:645-647. Pharmaceutical Research Manufacturers America [PhRMA] European Federation Pharmaceutical Industries Associations [EFPIA].July 18, 2013. Doshi P, Jefferson T.JAMA Intern Med.2013;173:380-382. Vickers AJ.BMJ.2011;342:d2323. European Medicines Agency.November 30, 2010. Approaches Data Sharing Odame E, Burgess T, Arbuckle L, Belcin A, et al. Applied Clinical Trials. 2023. Brayne C, et al.The Lancet.2022;399.10324:517. Simon GE, Coronado G, DeBar LL, et al..Annals Int Med. 2017. [epub ahead print] Lo B, Goodman SN..JAMA Int Med. 2017:177;1241-1242. Tudur Smith C, Nevitt S, Appelbe D, et al..Trials. 2017;18:319-326. Munafo MR, Nosek BA, Bishop DVM, et al.. 2017;1:1-9. Weninger S, Carrillo MC, Dunn B, et al..Alzheimers Dement. 2016;12:631-632. Tudur Smith C, Hopkins C, Sydes M, Woolfall K, Clarke M, Murray G, Williamson P.April 2015. El Emam K, Rodgers S, Malin B.BMJ.2015;350:h1139. Sydes MR, Johnson AL, Meredith SK, Rauchenberger M, South A, Parmar MKB.Trials.2015;16:104. Kush R, Goldman M.NEJM.2014;370:2163-2165. Wilhelm EE, Oster E, Shoulson I.JAMA.2014;311:1201-1202. Ioannidis JA, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, Schulz KF, Tibshirani R.Lancet.2014;383:166-175. Mello MM, Francer JK, Wilenzick M, Teden P, Bierer BE, Barnes M.NEJM. 2013;369:1651-1658. Berman F, Cerf V.Science.2013;341:616-617. Tucker M.BMJ.2013;347:f4465. Eichler HG, Abadie E, Breckenridge A, Leufkens H, Rasi G.PLOS Med.2012;9:e1001202. Spertus JA.Circ Cardiovasc Qual Outcomes.2012;5:143-144. Hrynaszkiewicz I, Norton ML, Vickers AJ, Altman DG.BMJ.2010;340:c181. Hrynaszkiewicz I, Altman DG.Trials.2009;10:17. Piwowar HA, Becich MJ, Bilofsky H, Crowley RS.PLoS Med.2008;5:e183. Importance Transparency Miller JE, Wilenzick M, Ritcey N, Ross JS, Mello MM..BMJ Open. 2017;7:e017917. Miller JE, Korn D, Ross JS..BMJ Open. 2015;5:e009758. Scherer RW, Ugarte-Gil C, Schmucker C, Meerpohl JJ.J Clin Epidemiol.Epub February 13, 2015. Vale CL, Rydzewska LHM, Rovers MM, Emberson JR, Gueyffier F, Stewart LA.BMJ.2015;350:h1088. Ebrahim S, Sohani ZN, Montoya L, Agarwal A, Thorlund K, Mills EJ, Ioannidis JA.JAMA.2014;312:1024-1032. Manzoli L, Flacco ME, DAddario M, Capasso L, De Vito C, Marzuillo C, Villari P, Ioannidis JA.BMJ.2014;348:g3058. Zarin DA.NEJM.2013;369:468-469. Eichler HG, Ptavy F, Pignatti F, Rasi G.NEJM.2013;369:1577-1579. Christakis DA, Zimmerman FJ.JAMA.2013;310:2499-2500. Rodwin MA, Abramson JD.JAMA.2012;308:871-872. Gtzsche PC.Circ Cardiovasc Qual Outcomes.2012;5:236-237. Alsheikh-Ali AA, Qureshi W, Al-Mallah MH, Ioannidis JA.PLOS One.2011;6:e24357. Gtzsche PC.Trials.2011;12:249. Savage CJ, Vickers AJ.PLoS ONE.2009;4:e7078. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DB.JAMA.2007;297:2112-2120. Vickers AJ.Trials.2006;7:15. Patient Perspective Mello MM, Lieou V, Goodman SN..NEJM. 2018; 378:2202-2211. Lomas A.BMJ.2013;346:f2336. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries YODA Project Steering Committee Stakeholders Conference first conference YODA Project wa held June 7, 2012, Yale School Law New Haven, CT. data sharing conference brought together Steering Committee member well expert academia, government, industry guide YODA Project rhBMP-2 data dissemination process. objective conference to: Identify barrier challenge data sharing Discuss feature policy public sharing Medtronics research data rhBMP-2 Discuss strategy promote data sharing effort Ideas data sharing freely exchanged concrete list key recommendation regarding data release wa outlined. feedback wa incorporated policy procedure data release YODA Project. Photos Conference Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries University College London YODA Project Joint Meeting Facilitating Data Access Non-Industry Funded Research Yale University Open Data Access (YODA) Project brought together clinical researchers, research funders, patient advocates, stakeholder discus challenge sharing clinical trial data non-industry funded research. first half day included series presentation reviewing current policy principle data sharing industry non-industry funded studies. served prelude broader discussion need enhance data sharing effort among academically-based investigator possible collaboration UCL YODA Project. Several clinical trial identified potential test-cases sharing non-industry funded research. Meeting participant working identify next step implementing pilot project sharing data non-industry funded studies. Click following view presentation given throughout day. Given Joseph S. Ross, MD, MHS Yale-New Center Outcomes Research Evaluation Given Norman Williams, PhD University College London Given Trish Groves, MD BMJ Given Joseph S. Ross, MD, MHS Yale-New Center Outcomes Research Evaluation Given Catrin Tudur Smith, MSc, PhD University Liverpool Given Paul Burton, MD University Bristol Given Professor Lesley Stewart University York Given Iain Hrynaszkiewicz Nature Publishing Group Given Jennifer OCallaghan Wellcome Trust Given Cary P. Gross, MD, Joseph S. Ross, MD, MHS Yale-New Center Outcomes Research Evaluation Given Emma White, PhD Administrative Data Research Centre England Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Community Data Sharing Resources Initiatives sharing using data clinical trial scientific research yielding increasing data sharing resource available scientific community. YODA Project encourages exploration additional data sharing resources, including: : Alzheimers Disease Data Initiative (ADDI) house datasets tool allow increased data sharing Alzheimers disease related dementias.: consortium clinical study data provider facilitates access patient-level data clinical studies. Participating study sponsor include: Astellas, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eisai, GSK, Lilly, Novartis, Roche, Sanofi, Takeda, UCB ViiV Healthcare.: curated resource make data underlying scientific publication discoverable, freely reusable, citable. Dryad provides general-purpose home wide diversity datatypes.: Database material prepared Food Drug Administration, United States medical product regulator, including information clinical study trial performed evaluate safety efficacy drug approved use FDA.: Database material submitted European Medicines Agency, European Unions medical product regulator, including information clinical study trial performed evaluate safety efficacy drug medical device receive marketing authorization European Medicines Agencys Committee Human Medicinal Products (CHMP). per Policy 0070 publication clinical data, clinical overviews, summaries, study reports, statistical method individual patient record information available log European Medicines Agency account.: repository user make research output available citable, shareable discoverable manner.: online integrated research platform investigator search, access, analyze data global network study center accelerate research causes, prevention, treatment Alzheimers neurodegenerative diseases.: search engine Google help researcher locate online data freely available use.: Database material submitted Health Canada, Canadas medical product regulator, including information clinical study trial performed evaluate safety efficacy drug medical device approved use Health Canada.: Ascientifically independent, multi-disciplinary coalition global infectious disease community: data sharing resource anonymised patient-level data clinical trial sponsored LEO Pharma.: web-based data portal aggregates, harmonizes, organizes sleep clinical data thousand individual studied part cohort study clinical trial provides user suite tool facilitate data exploration data visualization.: listing NIH-supported data repository make data accessible reuse (e.g. BioLINCC, ClinicalTrials.gov, dbGaP, NIDDK, GenBank, etc.).: NIH-resource designed help navigate NIH-wide NIH Institute Center-specific biomedical data repository data sharing policies, including link webinars resource support data preparation, management access.: data sharing resource Pfizers clinical trials.Database material prepared Food Drug Administration, United States medical product regulator, including information clinical study trial performed evaluate safety efficacy high-risk medical device approved use FDA.:The PRO-ACT (Pooled Resource Open-access ALS Clinical Trials) platform house largest ALS clinical trial dataset ever created merging data existing publicly- privately-conducted ALS clinical trial generate invaluable resource accelerating discovery field ALS.: free digital library-laboratory provides one place research community broadly share, integrate analyze historical, patient-level data academic industry phase III cancer clinical trials.: partnership Association Research Libraries Center Open Science develop free, open data gathering, cleaning, linking, enhancing metadata describes research activity outputs.: collaboration among member Duke Clinical Research Institute, academia, private industry open clinical research data benefit broader research community.: independent general access electronic data repository search engine individual participant-level data metadata clinical trial conducted researcher academic, industry, foundation, non-profit entity identified, hosted, shared analyzed.: research data repository multi-disciplinary data, software, conference materials, educational informational content. Access Zenodos content open all, non-military purpose only. aware data sharing resource listed above? Let u know: Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Frequently Asked Questions (FAQs) Data Availability seeking summary-level data specific trial trial request Data Partner conduct analyses? YODA Project facilitating external investigator access clinical trial data made available Data Partners. access allows external investigator conduct independent analysis data. Requests Data Partners conduct analysis generally out-of-scope due resource limitations, considered case-by-case basis depending upon circumstance rationale. available data listed YODA Project website? trial listed website available sharing external investigator following approval research request. Data additional trial may also available sharing; however, trial listed website yet reviewed determine might issue would slow prevent sharing external investigators. particular trial interest listed Trials page,. possible share requested data externally, data made available upon review approval full data request, appropriate de-identification process completed. data cannot released, reason available provided requestor. Refer YODA (Section 4) information. difference CSR Summary full CSR? full Clinical Study Report (CSR) comprehensive overview clinical trial that, general, number 50 500 page provides information background rationale trial, complete description study sample, design, intervention main outcome measures, well thorough provision result primary secondary efficacy endpoint safety. CSR Summary brief overview that, general, number 5 20 page summarizes study plan results, including numerical summary efficacy safety results, study objective, criterion inclusion, methodology, etc. Users required pay fee accessing data YODA Project? No. data provided free charge. proposed research already conducted one YODA Project Data Partners? YODA Project notify requestors proposed research already conducted Data Partner. decision whether proceed solely requestor. similar Research Proposal ha already submitted YODA Project another requestor? Requestors encouraged reviewto determine similar research project already way. decision proceed solely requestor, encouraged YODA Project given need reproducible science. product interested litigation- still submit request data? may request clinical trial data partnering Data Partners, regardless litigation status. However, may certain data cannot shared various reasons, including reason related litigation. decision need made case-by-case basis. YODA Project notify requestor reason data set approved sharing. Informed Consents signed patient participating clinical study data requested allow sharing data external researchers? Patients, investigators, site agree participate clinical trial critical partner advancing medical knowledge. Sharing data advancement science medicine important goal permit patient participate trial help patients. Data Partners committed ensuring patient privacy maintained data clinical trial shared making certain spirit informed consent signed patient honored data shared research advance public health way protect patient confidentiality. may limit ability share data instance (refer [Section 1] information). Upon approval data request, researcher granted access participant-level study data devoid personally identifiable information; current best guideline de-identification data used. supporting documentation available trial? specific supporting documentation available depends trial may include following: collected datasets, annotated CRFs, data definition specifications, protocol amendments, analysis datasets, statistical analysis plans, and/or full clinical study reports. individuallists supporting documentation trial. Data Request Process process submitting data request YODA Project? Researchers need review , identify trial interest, login create new data request. Additional detail specified the. employee Data Partner sharing data YODA Project- follow data request process? No, process researcher affiliated with/employed Data Partner collaborating YODA Project, one partner company contracted vendors. Data Partner affiliates, please utilize established internal process gaining access data set research purposes. affiliated Yale University- follow data request process? Yes, interested investigator external Data Partner, including based Yale University (the site YODA Project), must follow YODA Project data request process. example Research Proposal use template? Yes, instruction available. Investigators also reviewas examples. SCOPUS ID required apply data? No, SCOPUS ID required. However, please provide SCOPUS ID one allow tracking submitted data request using established unique identifier. AScopus ID# unique author identifier Elseviers Scopus database, abstract citation database peer-reviewed biomedical literature. individual ha published article indexed conference abstract automatically assigned ID # Elsevier. every team member need complete Conflict Interest statement? Yes, Conflict Interest statement required Principal Investigator Key Personnel. Key Personnel access data analyze and/or report finding use data. every team member need complete Data Use Agreement Training? Principal Investigator Key Personnel data access need complete training. Data Use Agreement Training need completed every data request? No, Principal Investigator Key Personnel need complete training first data request (unless otherwise determined YODA Project). notified data request ha received? Yes, notification sent email address provided account creation upon data request receipt. second notification sent stating whether additional material required data request undergoing review. Research Assistant project- complete data request behalf PI? team member besides Principal Investigator complete data request. team member creates account using one third party log options, Principal Investigators information entered Project Personnel. email address person receive communication YODA Project entered Email field. Data Request Review Process criterion used review, make decision whether Research Proposal approved? YODA Project evaluate Research Proposals ensure proposal ha scientific merit, 1) scientific purpose clearly described; 2) data requested used create materially enhance generalizable scientific and/or medical knowledge inform science public health; 3) proposed research reasonably addressed using requested data. YODA Project unable verify scientific merit proposal, two independent peer review solicited investigator sufficient clinical expertise broader scientific community unaffiliated Data Partner YODA Project. Upon return independent, external reviews, YODA Project meet least one member YODA Project Steering Committee, also independently reviewed materials, order make final decision grant deny data access. Refer the(Section 3) information. question regarding data request submitted/plan submit YODA Project- contact? Questions regarding data request sent to. submitted Research Proposal YODA Project wa approved. write additional proposals, need approved YODA Project well? Yes, individual Research Proposal need submitted YODA Project, regardless whether previous proposal approved. Data Use Agreement institution ha question change DUA? DUA ha prepared considerable deliberation negotiation Yale University Data Partner, order best facilitate access data external investigators. Please note change made exceptional circumstances, required Federal State law. requested change need identified using Track Changes reviewed Yale University Office Sponsored Projects (OSP), well Data Partner. Please contactwith questions. use electronic signature Data Use Agreement (DUA)? No, DUA need printed, signed, emailed YODA Project () notification received YODA Project Research Proposal wa approved. long DUA valid? expiration date one year signing DUA, renewed additional time one-year period project ongoing. Upon project completion, investigator destroy copy data (if applicable) supporting documentation. Investigators shall provide certification evidencing destruction within 30 day expiration date. investigator publication accepted, right use data retained verification publication respond inquiry regarding publication five (5) year acceptance. data cannot used additional analysis. additional analysis require new application data access YODA Project. Data Access long take access requested data data request ha approved? time required make data available dependent several factors, including many request received given time, number trial requested, whether External Review required evaluate scientific merit proposal, whether data requested electronic format ha de-identified ready sharing external investigators, time required appropriately de-identify data. clarifying information received requestor, aim make decision regarding approval within 30 days, and, investigator ha returned signed DUA, provide access data within additional 30 days. access data? method data made available depend Data Partner. One possible method involve data made available approved requestors via password-protected personalized account secure (Safe Harbor) data sharing platform. Data Partners preferring method, access granted maximum three researcher per approved data request. relevant clinical trial data supporting documentation made available via platform. Data remain secure Safe Harbor platform downloadable copied. However, relevant associated materials, clinical study report protocols, downloadable secure Safe Harbor platform. addition, request granted solely redacted complete CSRs distributed directly, without access secure Safe Harbor platform. Another possible method providing data access approved requestors involves transfer data directly requestor via secure electronic data transfer system (after DUA ha signed parties). Depending system, data may need downloaded order used. Data Use received data secure data sharing platform. download data personal computer? No, data made available secure data sharing platform able downloaded copied. work data must take place within secure platform. able download supporting documentation analysis participant-level data (e.g., case report forms, protocols, CSRs)? Yes. participant-level data remain secure platform able downloaded copied, relevant associated materials, clinical study report protocols, downloadable secure platform. supporting documentation need destroyed upon DUA expiration. want use different analytical tool perform analyses, addition Stata? Researchers access Stata, R, RStudio, Notepad, OpenOffice. needed, researcher able upload additional data set secure platform. Researchers may also request additional analytical package made available secure data sharing platform YODA Project work Data Partner determine whether possible. YODA Project work researcher ensure project conducted within platform. report possible safety concern found data analysis? possible safety concern arises data analysis reported directly Data Partner immediately evaluation reporting appropriate Health Regulatory Authorities necessary. Appropriate contact information provided DUAs. May use data course teaching data analysis? No, data cannot accessed shared third party listed data request. precludes providing data student part teaching education efforts. YODA Project provide technical statistical support? YODA Project doe provide technical statistical support. analytical support, YODA Project facilitate contact Data Users Data Partners, consultation desired part Data User sufficient resource available part Data Partner. Transparency Data Partner know identity requestors? data request review process blinded YODA Project reviewer Data Partners. data access granted YODA Project post requestors identity, Research Proposal, summary Data Partner Due Diligence Assessment, scientific review external investigator YODA Project Steering Committee, YODA Projects decision grant deny data access. relationship YODA Project Data Partners? YODA Project independent, academic organization partnering Data Partners, removing perception influence access. YODA Project review request associated registration material ensure required information completely submitted, committed facilitating external access data scientific purposes. Data Partners given YODA Project full jurisdiction make decision regarding data access. YODA Project post Research Proposal publicly? Yes, every proposal posted YODA Project website, regardless approval status, along Principal Investigators name, summary Data Partner Due Diligence Assessment, scientific review external investigator YODA Project Steering Committee, YODA Projects decision grant deny data access. overview ofis available, list ofis made publicly available. Research result and/or publication also posted YODA Project website soon available. Data Partner interested partnering YODA Project- do? inquiry related partnering YODA Project share clinical trial data, please contact. Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Acknowledgements YODA Project would like acknowledge many individual contribution endeavor: YODA Project General Steering Committee MembersYODA Project Clinical Steering Committee MembersSystematic Review Team Oregon Health Science UniversitySystematic Review Team University YorkYODA Project 2012 Conference ParticipantsYODA Project ConsultantsYale Office General CouncilYale Office Sponsored Projects Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Contact Us Fields marked * required YODA Project expected continue evolve based feedback user community, Data Partners, general public, well overall experience. Please help improve project sharing comments.Name *(Required) Email *(Required) Comments *(Required)CAPTCHA Side navigation Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Request Data Instructions requesting data: Start reviewing , Identify data interest data interest listed, site Complete online data request requirement including: Names, degrees, SCOPUS IDs (if available) Key Personnel Project funding source (if applicable) form PI Key Personnel Research Proposal () Specify type data requested: redacted full CSRs IPD Certify information provided true, requested data used pursuit litigation commercial interest Submit data request Ready begin? Side navigation Request Data website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Conflict Interest Please complete Conflict Interest form either site , prefer. complete, receive email link download pdf. Please save pdf upload data request Conflict Interest tab. Side navigation Request Data website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Data Use Agreement Training Please complete YODA Project Data Use Agreement training, available or. complete, receive email link download pdf. Please save pdf upload data request Conflict Interest tab. Side navigation Request Data website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Data Request Review Process outline process YODA Project review process data requests, component discussed greater detail below. YODA Project Review: request data undergo review upon receipt YODA Project. review, YODA Project evaluate submitted request associated registration material ensure required information ha provided Research Proposal ha scientific merit. Refer the(Section 3) information. YODA Project contact requestor additional information clarification data request needed. Due Diligence Assessment: Requests data already available secure data sharing platform undergo Due Diligence Assessment Data Partner. Refer the(Section 4) information. External Review: Requests undergo External Review YODA Project unable verify scientific merit Research Proposal. Refer the(Section 5) information. YODA Project contact requestor decision made regarding data access. requestor required sign submit a. Depending Data Partner, data made available either via password-protected personalized account secure data sharing platform via Yale Secure File Transfer Service. Refer the(Section 7) information. Timeline Review YODA Project aim provide access data approved data request quickly possible. timeline data request review data access broken follows: YODA Project estimate decision grant deny data access made within 30 day receipt complete data request. time period may affected number trial requested, need External Review Research Proposal, and/or number request received overall. goal provide access data within 30 day YODA Projects receipt researcher signed Data Use Agreement. requestor notified timeline longer anticipated. Transparency Public Posting Requests YODA Project publicly post data request associated registration materials, including Research Proposals, summary Data Partners Due Diligence Assessment, External Reviews, YODA Projects decision grant deny data access. access denied, public report detailing reason provided. Public posting intended promote transparency clinical research public accountability YODA Project data release process. Side navigation Request Data website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Request CSR Summary Clinical Study Report (CSR) Summary document summarizes full CSR, providing high-level overview study plan results, including numerical summary efficacy safety results, study objective(s), criterion inclusion, methodology, etc. Data Partners committed making CSR Summaries available quickly possible. CSR Summaries already available theOthers may available eitheror the. interested CSR Summary listed Trials page EMA Health Canada, please use form page request it. Name(Required) First Last Email(Required) Enter Email Confirm Email NCT # (preferred) NCT # unknown, please provide another identifier, PMID #, ICTRP #, biomedical literature citation #Notes: NCT # unique identifier National Institutes Health ClinicalTrials.gov database. PMID # unique identifier National Library Medicines PubMed database. ICTRP # unique identifier World Health Organization's International Clinical Trials Registry Platform. provide unique identifier another database, please specific.Additional trial-specific informationCAPTCHA Side navigation Request Data website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Approved Data Requests YODA Project review data request ensure proposal ha scientific merit, 1) scientific purpose clearly described; 2) data requested used create materially enhance generalizable scientific and/or medical knowledge inform science public health; 3) proposed research reasonably addressed using requested data. Click one following Data Partners view approved data requests: Side navigation Request Data website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Trials Generic Name page list trial identified availablethis complete list trial available sharing. trial shared, Data Partners must confirm data location availability electronic format, confirm data availability conforms applicable partner agreements. trial listed gone process. continue add trial list regular basis.Dont see trial(s) looking for? Abiraterone acetate View Trials Enrollment*: 54 Enrollment*: 313 Enrollment*: 297 Enrollment*: 1209 Enrollment*: 66 Enrollment*: 164 Enrollment*: 57 Enrollment*: 47 Enrollment*: 66 Enrollment*: 47 Ablation Catheter View Trials Enrollment*: 172 Acetaminophen View Trials Enrollment*: 40 Ad26.COV2.S View Trials Enrollment*: 31831 Enrollment*: 44325 Enrollment*: 1085 Apalutamide View Trials Enrollment*: 90 Enrollment*: 1052 Enrollment*: 1207 Enrollment*: 982 Bapineuzumab View Trials Enrollment*: 1331 Enrollment*: 1121 Bedaquiline/TMC207 View Trials Enrollment*: 75 Enrollment*: 241 Enrollment*: 208 Bermekimab View Trials Enrollment*: 86 Enrollment*: 144 Bosentan View Trials Enrollment*: 116 Enrollment*: 58 Enrollment*: 64 Enrollment*: 36 Enrollment*: 157 Enrollment*: 36 Enrollment*: 132 Enrollment*: 188 Enrollment*: 163 Enrollment*: 128 Canagliflozin View Trials Enrollment*: 64 Enrollment*: 4401 Enrollment*: 4330 Enrollment*: 335 Enrollment*: 376 Enrollment*: 5813 Enrollment*: 218 Enrollment*: 279 Enrollment*: 678 Enrollment*: 1186 Carvykti View Trials Enrollment*: 126 Daratumumab View Trials Enrollment*: 45 Enrollment*: 106 Enrollment*: 522 Enrollment*: 265 Enrollment*: 242 Enrollment*: 101 Enrollment*: 706 Enrollment*: 304 Enrollment*: 737 Enrollment*: 124 Darunavir View Trials NCT02269917 Enrollment*: 1149 NCT02431247 Enrollment*: 725 Enrollment*: 1149 Enrollment*: 725 Enrollment*: 80 Enrollment*: 12 Enrollment*: 27 Enrollment*: 692 Enrollment*: 334 Enrollment*: 330 Decitabine View Trials Enrollment*: 326 Doxorubicin hydrochloride View Trials Enrollment*: 481 Enrollment*: 220 Epoetin alfa View Trials Enrollment*: 1000 Enrollment*: 1432 Enrollment*: 680 Enrollment*: 504 Enrollment*: 86 Enrollment*: 72 Enrollment*: 192 Enrollment*: 1302 Enrollment*: 1460 Enrollment*: 102 Esketamine View Trials NCT03434041 Enrollment*: 252 Enrollment*: 719 Enrollment*: 108 Enrollment*: 202 Enrollment*: 68 Enrollment*: 30 Enrollment*: 802 Enrollment*: 252 Enrollment*: 230 Enrollment*: 68 Ethinyl estradiol View Trials Enrollment*: 201 Etravirine View Trials Enrollment*: 33 Galantamine View Trials Enrollment*: 978 Enrollment*: 130 Enrollment*: 215 Enrollment*: 415 Enrollment*: 2051 Enrollment*: Enrollment*: Enrollment*: 1063 Enrollment*: 974 Enrollment*: 973 Galantamine hydrobromide View Trials Enrollment*: 285 Enrollment*: 83 Golimumab View Trials Enrollment*: 208 Enrollment*: 84 Enrollment*: 198 Enrollment*: 309 Enrollment*: 7 Enrollment*: 103 Enrollment*: 144 Enrollment*: 433 Enrollment*: 480 Enrollment*: 173 Graded exercise therapy View Trials Enrollment*: 211 Guselkumab View Trials Enrollment*: 184 Enrollment*: 872 Enrollment*: 837 Enrollment*: 192 Enrollment*: 1048 Enrollment*: 119 Enrollment*: 78 Enrollment*: 992 Enrollment*: 293 HEALOS Leopard Cage View Trials Enrollment*: 138 Ibrutinib View Trials Enrollment*: 280 Enrollment*: 523 Enrollment*: 838 Enrollment*: 229 Enrollment*: 391 Enrollment*: 181 Enrollment*: 45 Enrollment*: 578 Enrollment*: 133 Enrollment*: 115 Ibuprofen View Trials Enrollment*: 85 Enrollment*: 24 Infliximab View Trials Enrollment*: 607 Enrollment*: 378 Enrollment*: 249 Enrollment*: 28 Enrollment*: 139 Enrollment*: 73 Enrollment*: 347 Enrollment*: 101 Enrollment*: 279 Enrollment*: Levofloxacin View Trials Enrollment*: 738 Enrollment*: 1109 Macitentan View Trials Enrollment*: 20 Enrollment*: 85 Enrollment*: 265 Enrollment*: 289 Enrollment*: 60 Enrollment*: 178 Enrollment*: 226 Enrollment*: 742 Mebendazole View Trials Enrollment*: 100 Enrollment*: 396 Enrollment*: 295 Methylphenidate HCl View Trials Enrollment*: 145 Enrollment*: 284 Enrollment*: 229 Enrollment*: 357 Enrollment*: 89 Enrollment*: 78 Enrollment*: 436 Enrollment*: 1323 Enrollment*: 279 Enrollment*: 402 Miglustat View Trials Enrollment*: 472 Minoxidil 5% Womens Foam View Trials Enrollment*: 404 Enrollment*: 322 Mouth Rinse, potassium oxalate 1.4% View Trials Enrollment*: 375 Enrollment*: 153 Enrollment*: 226 Enrollment*: 80 N/A View Trials Enrollment*: 6273 Enrollment*: 125 Enrollment*: 62 Enrollment*: 196 Norelgestromin View Trials Enrollment*: 1751 Norgestimate View Trials Enrollment*: 355 Paliperidone View Trials Enrollment*: 841 Enrollment*: 328 Enrollment*: 407 Enrollment*: 294 Enrollment*: 1812 Enrollment*: 450 Enrollment*: 235 Enrollment*: 5 Enrollment*: 201 Enrollment*: 768 Paliperidone palmitate View Trials Enrollment*: 306 Enrollment*: 1429 Enrollment*: 201 Enrollment*: 323 Enrollment*: 212 Enrollment*: 546 Enrollment*: 1044 Enrollment*: 769 Enrollment*: 667 Enrollment*: 509 Rafivirumab/Foravirumab View Trials Enrollment*: 240 Enrollment*: 48 Enrollment*: 140 Rilematovir View Trials NCT04068792 Enrollment*: 22 Enrollment*: 22 Rilpivirine View Trials Enrollment*: 680 Enrollment*: 694 Risperidone View Trials Enrollment*: 463 Enrollment*: 141 Enrollment*: 160 Enrollment*: 39 Enrollment*: 225 Enrollment*: 31 Enrollment*: 355 Enrollment*: 24 Enrollment*: 40 Enrollment*: 100 Selexipag View Trials Enrollment*: 108 Enrollment*: 74 Enrollment*: 34 Enrollment*: 1156 Simeprevir View Trials currently trial product Sirukumab View Trials Enrollment*: 559 Enrollment*: 122 Enrollment*: 878 Enrollment*: 1670 Terconazole View Trials Enrollment*: 160 TEST GENERIC NAME View Trials currently trial product Topiramate View Trials Enrollment*: 72 Enrollment*: 371 Enrollment*: 385 Enrollment*: 56 Enrollment*: 47 Enrollment*: 178 Enrollment*: 100 Enrollment*: 60 Enrollment*: 80 Enrollment*: 211 Toreforant View Trials Enrollment*: 62 Enrollment*: 88 Trabectedin View Trials Enrollment*: Enrollment*: 121 Enrollment*: 29 Enrollment*: 34 Enrollment*: 50 Enrollment*: 99 Enrollment*: 75 Enrollment*: 1803 Enrollment*: 270 Enrollment*: 577 Triangular Titanium Implants View Trials Enrollment*: 51 Enrollment*: 103 Enrollment*: 103 Enrollment*: 148 Enrollment*: 194 Ustekinumab View Trials Enrollment*: 961 NCT02698475 Enrollment*: 44 Enrollment*: 249 Enrollment*: 386 Enrollment*: 516 Enrollment*: 44 Enrollment*: 274 Enrollment*: 173 Enrollment*: 356 Enrollment*: 315 website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Login Login via CAS: Username Email Address Password Remember Connect [openid_connect_generic_login_button] Side navigation website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries YODA Project Metrics graph display complete data requests* received YODA Project since October 2014. information updated quarterly (last update: April 1, 2024). detail data requests, well additional metrics, use following links: *All request date Johnson & Johnson clinical trial data. such, metric specific Johnson & Johnson. Data Requests Year-Quarter View Graphic Chart View Tabular Data difficulty reading viewing graphic chart, recommended view tabular data instead. Year/QuarterNot ApprovedWithdrawn/ClosedUnder Review/RevisionsApproved (pending signed DUA data preparation)Data access granted (analyses progress manuscript review)PublishedConcluded project summaryIncomplete without result reported2014-Q4002510002015-Q1000740002015-Q2023570002015-Q30246100002015-Q40347100002016-Q104411180002016-Q206213250002016-Q306311350002016-Q406411392002017-Q10653513002017-Q20627513312017-Q306110513312017-Q40725565822018-Q107155771032018-Q20711052101532018-Q3083752161632018-Q40901253181832019-Q10911253181832019-Q20121756212032019-Q30133860222032019-Q40148766232032020-Q101641679232032020-Q211791284252542020-Q311841791292542020-Q4121310103342642021-Q112207114382752021-Q212258110423452021-Q3122411108493562021-Q41221016109503862022-Q1122223119603862022-Q212655132634282022-Q312799130734392022-Q4130 9121267544192023-Q11306131378144262023-Q2 1314181318644272023-Q31343111398945302023-Q413551313110046352024-Q1241 4151371054635 Filter year 2014-Q4 2015-Q1 2015-Q2 2015-Q3 2015-Q4 2016-Q1 2016-Q2 2016-Q3 2016-Q4 2017-Q1 2017-Q2 2017-Q3 2017-Q4 2018-Q1 2018-Q2 2018-Q3 2018-Q4 2019-Q1 2019-Q2 2019-Q3 2019-Q4 2020-Q1 2020-Q2 2020-Q3 2020-Q4 2021-Q1 2021-Q2 2021-Q3 2021-Q4 2022-Q1 2022-Q2 2022-Q3 2022-Q4 2023-Q1 2023-Q2 2023-Q3 2023-Q4 2024-Q1 stacked group chart visualizing statistic Data Requests Year-Quarter. Hide Approved Hide Withdrawn/Closed Hide Review/Revisions Hide Approved (pending signed DUA data preparation) Hide Data access granted (analyses progress manuscript review) Hide Published Hide Concluded project summary Hide Incomplete without result reported Side navigation Data Requests Inquiries CSR Summaries website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Submitted Requests Use Johnson & Johnson Data Metrics last updated May 1, 2024. 400 Data Requests Received 89 Requests Requiring Scientific Revision Prior Approval 6.50 Median Number Days YODA Project Review [IQR, 2 13] 95.3% Requests IPD supporting documentation 4.7% Requests full CSR Data Request Decision 94.0%Approved [n=376]2.8%Under Review / Revisions Requested [n=11]3.3%Revisions Received / Closed prior Decision [n=13]0.5%Not Approved [n=2] pie chart visualizing statistic Data Request Decision. Purpose Analysis horizontal bar chart visualizing statistic Purpose Analysis. New Question (50.3%)Meta-Analysis (47.5%)Validation (23.3%)Clinical Prediction, Risk Prediction (26.8%)Statistical Methods (20.3%)Clinical Trial Methods (15.5%)Comparison Group (9%)Pilot/Preliminary Research (5.8%)Other (11%) Number Trials Requested 25.3%Requests 1 trial35.0%Requests 2-4 trials31.8%Requests 5-19 trials8.3%Requests 20+ trial pie chart visualizing statistic Number Trials Requested. 56.0% Multiple trials: product 33.1% Multiple trials: Different product disease category 10.9% Multiple trials: Different product different disease category Primary Investigator Affiliations horizontal bar chart visualizing statistic Primary Investigator Affiliations. Academia (92.3%)Industry (5.8%)Government (1.8%) Side navigation Data Requests Inquiries CSR Summaries website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Details Data Requests Use Johnson Johnson Data Request listing updated daily Requests YODA Project post proposal data access ha granted denied. Approved Requests YODA Project post approved proposal data access ha granted. Withdrawn Requests following data request could fulfilled due patient privacy concerns, data element availability, data security concerns, lack research proposal clarity. YODA Project post withdrawn/unapproved proposal time decision made. Show Requests Filters Filters list Close Reset Search Protocol Number Product Interest PI Country PI Affiliation Year Data Access NO. Trials Provided Results Project Status Reset YODA Protocol Number 2022-5104 Product(s) Interest REMICADE (Infliximab) SIMPONI (Golimumab) STELARA (Ustekinumab) No. Trials Provided 6 Published Publications Available! Biomarkers Predicting Long-term Outcomes Ulcerative Colitis Principal Investigator Rirong Chen Reports & Publications Protocol & Associated Materials YODA Protocol Number 2021-4846 Product(s) Interest ERLEADA (Apalutamide) No. Trials Provided 1 Submitted YODA Project Review Publication Available! External Validation Prognostic Model Overall Survival Men Metastatic Castration-Resistant Prostate Cancer Principal Investigator Susan Halabi Duke University Reports & Publications Protocol & Associated Materials YODA Protocol Number 2021-4822 Product(s) Interest STELARA (Ustekinumab) No. Trials Provided 2 Ongoing Publication Available! Comparative Efficacy Ustekinumab Infliximab One Year Outcomes Among Biologic-nave Induction Responders Crohns Disease Principal Investigator Neeraj Narula Reports & Publications Cited Protocol & Associated Materials YODA Protocol Number 2021-4779 Product(s) Interest REMICADE (Infliximab) STELARA (Ustekinumab) SIMPONI (Golimumab) No. Trials Provided 6 Published Publication Available! Predictors Placebo Response Remission Ulcerative Colitis Crohns Disease Principal Investigator Neeraj Narula Reports & Publications Cited Protocol & Associated Materials YODA Protocol Number 2021-4778 Product(s) Interest STELARA (Ustekinumab) No. Trials Provided 3 Published Publication Availible! Comparative Effectiveness Biologics Endoscopic Healing Ileum Colon Crohns Disease Principal Investigator Neeraj Narula Reports & Publications Cited Protocol & Associated Materials YODA Protocol Number 2021-4757 Product(s) Interest REMICADE (Infliximab) No. Trials Provided 2 Published Publication Available! Comparison Rapidity Clinical Response Infliximab Tofacitinib Ulcerative Colitis. Principal Investigator Neeraj Narula Hamilton Health Sciences Reports & Publications Protocol & Associated Materials YODA Protocol Number 2021-4684 Product(s) Interest STELARA (Ustekinumab) No. Trials Provided 3 Published Publications Available! Dominant Patient Reported Outcomes Predicting Mucosal Healing Crohns Disease Principal Investigator Neeraj Narula Reports & Publications Cited Protocol & Associated Materials YODA Protocol Number 2021-4637 Product(s) Interest SPRAVATO (Esketamine) No. Trials Provided 3 Published Publication Available! Data-sharing re-analysis main study assessed European Medicines Agency cross-sectional study EPARs Principal Investigator Florian Naudet University Rennes 1 Reports & Publications Protocol & Associated Materials YODA Protocol Number 2021-4602 Product(s) Interest STELARA (Ustekinumab) REMICADE (Infliximab) No. Trials Provided 4 Published Publication Available! Modified Multiplier SES-CD (MM-SES-CD) Predicting Endoscopic Remission Crohns Disease Principal Investigator Neeraj Narula Reports & Publications Cited Protocol & Associated Materials YODA Protocol Number 2021-4599 Product(s) Interest DARZALEX (Daratumumab) No. Trials Provided 6 Published Publication Available! Outcomes Early versus Late Response Daratumumab Patients Refractory/Relapsed Newly Diagnosed Multiple Myeloma Principal Investigator Jiasheng Wang MetroHealth Medical Center Reports & Publications Cited Protocol & Associated Materials website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Clinical Trial Inquiries CSR Summary Requests Metrics last updated May 1, 2024. 468 Inquiries Received Trials Listed Site 493 Unique Trials Requested Answered Inquiries 14.0 Median Number Days Response Inquiry [IQR, 7.0-31.5] 98.5% Inquiries Answered Date 50.8% Inquiries (where trial(s) made available) Led Full Data Request Total Unique Trials Requested Across Answered Inquiries 51.7%Trials Made Available48.3%Trials Cannot Made Available pie chart visualizing statistic Total Unique Trials Requested Across Answered Inquiries. Trials Unavailable horizontal bar chart visualizing statistic Trials Unavailable. Trial completed < 18 mo. ago ongoing (45.8%)Regulatory approval yet received (17.2%)Phase 1; investigator invited submit proposal (17.2%) Data Partner alliance member ha agreed share (8.8%)Data cannot converted electronic format (4.2%)Materials available English (3.8%)Trial scope (i.e., observational, etc.) (2.5%)Data subject partner agreement; researcher advised contact partner (2.1%) Response Trial Inquiries View Graphic Chart View Tabular Data difficulty reading viewing graphic chart, recommended view tabular data instead. Year/QuarterTrials Made Available Response Inquiry2014-Q432015-Q1182015-Q2212015-Q3262015-Q4362016-Q1662016-Q2812016-Q3882016-Q4922017-Q1982017-Q21002017-Q31112017-Q41142018-Q11282018-Q21312018-Q31342018-Q41362019-Q11522019-Q21602019-Q31612019-Q41712020-Q11952020-Q21962020-Q31992020-Q42012021-Q12012021-Q22052021-Q32062021-Q42112022-Q12252022-Q22262022-Q32282022-Q42332023-Q12482023-Q22482023-Q32492023-Q42512024-Q12552024-Q2255 Filter year 2014-Q4 2015-Q1 2015-Q2 2015-Q3 2015-Q4 2016-Q1 2016-Q2 2016-Q3 2016-Q4 2017-Q1 2017-Q2 2017-Q3 2017-Q4 2018-Q1 2018-Q2 2018-Q3 2018-Q4 2019-Q1 2019-Q2 2019-Q3 2019-Q4 2020-Q1 2020-Q2 2020-Q3 2020-Q4 2021-Q1 2021-Q2 2021-Q3 2021-Q4 2022-Q1 2022-Q2 2022-Q3 2022-Q4 2023-Q1 2023-Q2 2023-Q3 2023-Q4 2024-Q1 2024-Q2 stacked group chart visualizing statistic Response Trial Inquiries. Hide Trials Made Available Response Inquiry CSR Summaries Requested Provided View Graphic Chart View Tabular Data difficulty reading viewing graphic chart, recommended view tabular data instead. Year/QuarterCSR Summaries AvailableCSR Summaries Available2015-Q1122015-Q2122015-Q3122015-Q4232016-Q1732016-Q21262016-Q31262016-Q41262017-Q11562017-Q21562017-Q31662017-Q41762018-Q11782018-Q22182018-Q32192018-Q421102019-Q121112019-Q222112019-Q323182019-Q423182020-Q123182020-Q223182020-Q327182020-Q427182021-Q227182021-Q327182022-Q128182022-Q254182022-Q354192022-Q455192023-Q155202023-Q255202023-Q355212023-Q455212024-Q155212024-Q25521 Filter year 2015-Q1 2015-Q2 2015-Q3 2015-Q4 2016-Q1 2016-Q2 2016-Q3 2016-Q4 2017-Q1 2017-Q2 2017-Q3 2017-Q4 2018-Q1 2018-Q2 2018-Q3 2018-Q4 2019-Q1 2019-Q2 2019-Q3 2019-Q4 2020-Q1 2020-Q2 2020-Q3 2020-Q4 2021-Q2 2021-Q3 2022-Q1 2022-Q2 2022-Q3 2022-Q4 2023-Q1 2023-Q2 2023-Q3 2023-Q4 2024-Q1 2024-Q2 stacked group chart visualizing statistic CSR Summaries Requested Provided. Hide CSR Summaries Available Hide CSR Summaries Available Side navigation Data Requests Inquiries CSR Summaries website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Trials Determined Unavailable trial listed page determined unavailable. YODA Project periodically reevaluates trial unavailable time inquiry following reasons: Trial ongoing wa completed <18 month ago Regulatory approval yet received reevaluation identifies trial made available, original requestor(s) contacted. list available request also found page. Unavailable trial Statistics unavailable trials. NCT# Generic Product Name Number Inquiries Received Reason Trial Available NCT02670395 N/A 1 Trial phase 1 NCT01274507 N/A 1 Trial phase 1 NCT03085108 N/A 1 Trial phase 1 NCT03180853 N/A 1 Trial ongoing/completed <18 month ago NCT04080752 N/A 1 Trial ongoing/completed <18 month ago NCT04644770 N/A 1 Trial ongoing/completed <18 month ago NCT02663193 Abiraterone Acetate 1 Trial scope (i.e., observational, etc.) NCT04447040 Acetaminophen 1 Trial ongoing/completed <18 month ago NCT02564523 Ad26.ZEBOV 1 Regulatory approval yet received NCT04436276 Ad26.COV2.S 1 Trial ongoing/completed <18 month ago NCT04505722 Ad26.COV2.S 5 Trial ongoing/completed <18 month ago NCT04614948 Ad26.COV2.S 2 Trial ongoing/completed <18 month ago NCT04765384 Ad26.COV2.S 1 Trial ongoing/completed <18 month ago NCT02788045 Ad26.Mos.HIV 1 Trial ongoing/completed <18 month ago NCT03795441 Ad26.RSV.preF 1 Trial phase 1 NCT02315703 Adenovirus Serotype 26 1 Trial ongoing/completed <18 month ago NCT04908683 Adenovirus Serotype 26 1 Trial ongoing/completed <18 month ago NCT04538664 Amivantamab 2 Trial ongoing/completed <18 month ago NCT02609776 Amivantamab 5 Trial ongoing/completed <18 month ago NCT03559192 Aticaprant 1 Regulatory approval yet received NCT01254773 Bapineuzumab 1 Data cannot converted electronic format NCT01284387 Bapineuzumab 1 Data cannot converted electronic format NCT02354014 Bedaquiline 1 Trial ongoing/completed <18 month ago NCT04988308 Bermekimab 2 Trial ongoing/completed <18 month ago NCT04171518 CAST-102-SYST 1 Trial ongoing/completed <18 month ago NCT01704040 CNTO3157 1 Trial phase 1 JNS001-JPN03 Concerta 1 Trial material available English NCT03201965 Daratumumab 1 Trial ongoing/completed <18 month ago NCT03652064 Daratumumab 1 Trial ongoing/completed <18 month ago NCT03320707 Daratumumab 1 Trial ongoing/completed <18 month ago NCT01998971 DARZALEX 2 Trial ongoing/completed <18 month ago NCT02076009 DARZALEX 1 Trial ongoing/completed <18 month ago NCT02195479 DARZALEX 3 Trial ongoing/completed <18 month ago NCT02316106 DARZALEX 1 Trial ongoing/completed <18 month ago NCT02477891 DARZALEX 1 Trial ongoing/completed <18 month ago NCT02852837 DARZALEX 1 Trial ongoing/completed <18 month ago NCT02874742 DARZALEX 2 Trial ongoing/completed <18 month ago NCT03217812 DARZALEX 1 Trial ongoing/completed <18 month ago NCT03277105 DARZALEX 1 Trial ongoing/completed <18 month ago NCT03652064 DARZALEX 1 Trial ongoing/completed <18 month ago NCT03901963 DARZALEX 1 Trial ongoing/completed <18 month ago NCT02195479 DARZALEX 1 Trial ongoing/completed <18 month ago NCT01998971 DARZALEX 1 Trial ongoing/completed <18 month ago NCT03412565 DARZALEX 1 Trial ongoing/completed <18 month ago NCT05250973 DARZALEX 1 Trial ongoing/completed <18 month ago NCT03896061 ECHELON FLEX GST 1 Trial scope (i.e., observational, etc.) NCT00799864 EDURANT 1 Trial ongoing/completed <18 month ago NCT00086684 ELMIRON 1 Data Partner alliance member ha agreed share NCT00236990 ELMIRON 1 Data Partner alliance member ha agreed share NCT02365597 Erdafitinib 1 Trial ongoing/completed <18 month ago NCT03390504 Erdafitinib 1 Trial ongoing/completed <18 month ago NCT04083976 Erdafitinib 1 Trial ongoing/completed <18 month ago NCT05316155 Erdafitinib 1 Trial phase 1 NCT01946204 ERLEADA 3 Trial ongoing/completed <18 month ago NCT01171898 ERLEADA 1 Regulatory approval yet received NCT02489318 ERLEADA 3 Trial ongoing/completed <18 month ago NCT01780259 Esketamine 1 Trial phase 1 NCT01998958 Esketamine 1 Regulatory approval yet received NCT02345148 Esketamine 1 Trial phase 1 NCT02417064 Esketamine 1 Regulatory approval yet received NCT02418585 Esketamine 1 Regulatory approval yet received NCT02422186 Esketamine 2 Regulatory approval yet received NCT02418585 Esketamine 2 Regulatory approval yet received NCT02493868 Esketamine 1 Regulatory approval yet received NCT02497287 Esketamine 2 Regulatory approval yet received NCT02682225 Esketamine 1 Trial phase 1 NCT02857777 Esketamine 1 Trial phase 1 NCT03039192 Esketamine 1 Regulatory approval yet received NCT04338321 Esketamine 1 Trial ongoing/completed <18 month ago NCT02919579 Esketamine 1 Trial phase 1 NCT03185819 Esketamine 1 Trial ongoing/completed <18 month ago NCT04599855 Esketamine 1 Trial ongoing/completed <18 month ago NCT04899336 ExPEC9V 1 Trial ongoing/completed <18 month ago NCT01964651 FAAH inhibitor 1 Trial phase 1 NCT01008553 Fentanyl 1 Trial material available English NCT01008618 Fentanyl 1 Trial material available English NCT01703481 FGFR kinase inhibitor 1 Trial ongoing/completed <18 month ago NCT02301234 Fulranumab 1 Trial ongoing/completed <18 month ago NCT03298542 Golimumab 1 Trial ongoing/completed <18 month ago NCT00925574 Guselkumab 1 Trial phase 1 NCT01484587 Guselkumab 1 Trial phase 1 NCT01866007 Guselkumab 2 Trial phase 1 NCT02155192 Guselkumab 1 Trial phase 1 NCT03090100 Guselkumab 1 Regulatory approval yet received NCT03466411 Guselkumab 1 Trial ongoing/completed <18 month ago NCT03998683 Guselkumab 1 Trial ongoing/completed <18 month ago NCT01109069 IMBRUVICA 1 Data Partner alliance member ha agreed share NCT01578707 IMBRUVICA 1 Regulatory approval yet received NCT01599949 IMBRUVICA 1 Data Partner alliance member ha agreed share NCT01611090 IMBRUVICA 1 Data Partner alliance member ha agreed share NCT01646021 IMBRUVICA 1 Regulatory approval yet received NCT01704963 IMBRUVICA 1 Regulatory approval yet received NCT01779791 IMBRUVICA 1 Data Partner alliance member ha agreed share NCT01855750 IMBRUVICA 2 Trial ongoing/completed <18 month ago NCT01973387 IMBRUVICA 1 Data Partner alliance member ha agreed share NCT01980628 IMBRUVICA 2 Regulatory approval yet received NCT01744691 IMBRUVICA 1 Regulatory approval yet received NCT01325701 IMBRUVICA 1 Regulatory approval yet received NCT02165397 IMBRUVICA 1 Regulatory approval yet received NCT02910583 IMBRUVICA 1 Trial ongoing/completed <18 month ago NCT01243073 Imetelstat 1 Regulatory approval yet received NCT01731951 Imetelstat 1 Trial ongoing/completed <18 month ago NCT02426086 Imetelstat 1 Trial ongoing/completed <18 month ago NCT02598661 Imetelstat 2 Trial ongoing/completed <18 month ago NCT05574959 Intraocular lens 1 Trial ongoing/completed <18 month ago NCT00758030 INVEGA 1 Trial phase 1 NCT00791349 INVEGA 1 Trial phase 1 NCT00791622 INVEGA 1 Trial phase 1 NCT03345342 INVEGA 1 Trial ongoing/completed <18 month ago N/A (sponsor ID: R092670-JPN-4) INVEGA SUSTENNA 1 Trial material available English NCT01559272 INVEGA SUSTENNA 1 Trial ongoing/completed <18 month ago NCT02065791 INVOKANA 1 Trial ongoing/completed <18 month ago NCT04252287 INVOKANA 1 Trial ongoing/completed <18 month ago NCT02609776 JNJ-61186372 1 Trial ongoing/completed <18 month ago NCT02715011 JNJ-63709178 1 Trial ongoing/completed <18 month ago NCT02908906 JNJ-63723283 1 Trial ongoing/completed <18 month ago NCT03915379 JNJ-67571244 1 Trial ongoing/completed <18 month ago NCT04181827 Ciltacabtagene autoleucel 4 Trial ongoing/completed <18 month ago NCT03891524 JNJ-70033093 1 Trial ongoing/completed <18 month ago NCT04811560 JNJ-75276617 1 Trial ongoing/completed <18 month ago NCT05441501 JNJ-80038114 1 Trial ongoing/completed <18 month ago NCT02094365 Lumicitabine 1 Regulatory approval yet received NCT04577833 Niraparib 1 Trial ongoing/completed <18 month ago NCT00396565 PALIPERIDONE 2 Trial material available English NCT01561898 PALIPERIDONE 1 Trial material available English NCT01006265 Ponesimod 1 Regulatory approval yet received NCT00855335 PREZISTA 1 Trial ongoing/completed <18 month ago NCT01619527 PREZISTA 1 Trial phase 1 N/A (sponsor ID: TMC114-C105) PREZISTA 1 Trial phase 1 N/A (sponsor ID: TMC114-C114) PREZISTA 2 Trial phase 1 N/A (sponsor ID: TMC114-C116) PREZISTA 1 Trial phase 1 N/A (sponsor ID: TMC114-C143) PREZISTA 1 Trial phase 1 N/A (sponsor ID: TMC114IFD1001) PREZISTA 1 Trial phase 1 NCT00814801 RAZADYNE 2 Trial material available English N/A(sponsor ID: GAL-JPN-3) RAZADYNE 1 Trial material available English N/A (sponsor ID: GAL-PED-1001 (CR010954)) RAZADYNE 1 Trial scope (i.e., observational, etc.) N/A (sponsor ID: RIS-BEL-24) RISPERDAL 1 Regulatory approval yet received N/A (sponsor ID: RIS-INT-26) RISPERDAL 1 Data cannot converted electronic format NCT00253110 (sponsor ID:RIS-USA-79) RISPERDAL 1 Data cannot converted electronic format NCT00240708 (sponsor ID:RIS-JPN-S31) RISPERDAL 1 Data cannot converted electronic format N/A (sponsor ID: RIS-INT-39) RISPERDAL 1 Regulatory approval yet received N/A (sponsor ID: RIS-NED-9) RISPERDAL 1 Regulatory approval yet received NCT00246194 RISPERDAL CONSTA 1 Trial phase 1 NCT00330551 RISPERDAL CONSTA 1 Trial phase 1 NCT04988295 Rybrevant 1 Trial ongoing/completed <18 month ago NCT03374475 Seltorexant 1 Trial ongoing/completed <18 month ago NCT04513912 Seltorexant 1 Trial ongoing/completed <18 month ago NCT04116736 senofilcon 1 Trial ongoing/completed <18 month ago NCT00727987 SIMPONI 1 Data Partner alliance member ha agreed share NCT00771251 SIMPONI 1 Data Partner alliance member ha agreed share NCT04816513 STELARA 1 Trial phase 1 NCT03981744 STELARA 1 Trial ongoing/completed <18 month ago NCT04075591 STAR S4 IR Excimer laser System 1 Trial ongoing/completed <18 month ago NCT03399799 TALVEY 1 Trial ongoing/completed <18 month ago NCT04640623 TAR-200 1 Trial ongoing/completed <18 month ago NCT03145181 TECLISTAMAB 2 Trial phase 1 NCT04557098 TECLISTAMAB 2 Trial ongoing/completed <18 month ago NCT05991960 TECNIS Odyssey IOL 1 Trial ongoing/completed <18 month ago NCT02359890 THERMOCOOL SMARTTOUCH (RF ablation treatment) 1 Trial ongoing/completed <18 month ago TOPAMAX 1 Data cannot converted electronic format TOPAMAX 1 Data cannot converted electronic format TOPAMAX 1 Data cannot converted electronic format TOPAMAX 1 Data cannot converted electronic format TOPAMAX 1 Data cannot converted electronic format NCT01081795 TOPAMAX 2 Trial material available English NCT01112267 Tramadol HCl 1 Data cannot converted electronic format NCT02207231 TREMFYA 1 Trial ongoing/completed <18 month ago NCT02207244 TREMFYA 1 Trial ongoing/completed <18 month ago NCT02641730 TREMFYA 1 Regulatory approval yet received NCT03628924 TREMFYA 1 Trial ongoing/completed <18 month ago NCT04882098 TREMFYA 1 Trial ongoing/completed <18 month ago NCT04147338 TREMFYA 1 Trial phase 1 NCT03818035 TREMFYA 1 Trial ongoing/completed <18 month ago NCT05299606 Transbronchial Microwave Ablation 1 Trial ongoing/completed <18 month ago N/A (sponsor ID: TRAM-PEDS-001) ULTRAM ULTRAM ER 1 Trial phase 1 N/A (sponsor ID: TRAM-PEDS-005) ULTRAM ULTRAM ER 1 Trial phase 1 N/A (sponsor ID: TRAM-PEDS-006) ULTRAM ULTRAM ER 1 Trial phase 1 NCT04266756 UPTRAVI 1 Trial phase 1 NCT02627768 Ustekinumab 1 Trial ongoing/completed <18 month ago NCT00103506 VELCADE 1 Data subject partner agreement; researcher advised contact Data Partner NCT00111319 VELCADE 1 Data subject partner agreement; researcher advised contact Data Partner NCT00507416 VELCADE 1 Data subject partner agreement; researcher advised contact Data Partner NCT00908232 VELCADE 1 Data subject partner agreement; researcher advised contact Data Partner NCT00431769 VELCADE 1 Data subject partner agreement; researcher advised contact Data Partner PMID: 19036115 VELCADE 1 Data subject partner agreement; researcher advised contact Data Partner NCT00403767 XARELTO 8 Data Partner alliance member ha agreed share NCT00809965 XARELTO 1 Data Partner alliance member ha agreed share regulatory approval yet received NCT00440193 XARELTO 1 Data Partner alliance member ha agreed share NCT00395772 XARELTO 1 Data Partner alliance member ha agreed share NCT00439725 XARELTO 1 Data Partner alliance member ha agreed share NCT00439777 XARELTO 1 Data Partner alliance member ha agreed share NCT00494871 XARELTO 1 Data Partner alliance member ha agreed share NCT01830543 XARELTO 1 Data Partner alliance member ha agreed share NCT01877915 XARELTO 1 Data Partner alliance member ha agreed share NCT02111564 XARELTO 1 Data Partner alliance member ha agreed share N/A Xylometazoline 1 Trial scope (i.e., observational, etc.) NCT00910754 ZYTIGA 1 Trial phase 1 NCT02230046 ZYTIGA 1 Trial phase 1 NCT03748641 ZYTIGA 2 Trial ongoing/completed <18 month ago Total: 201 Total: 231 Reevaluated trial available request: NCT# Generic Product Name Number Inquiries Received Reason Trial wa Originally Available NCT00574288 DARZALEX 1 Trial ongoing/completed <18 month ago NCT01615029 DARZALEX 1 Trial ongoing/completed <18 month ago NCT02252172 DARZALEX 3 Regulatory approval yet received NCT02951819 DARZALEX 1 Trial ongoing/completed <18 month ago NCT02195869 IMBRUVICA 1 Regulatory approval yet received NCT01032629 INVOKANA 3 Regulatory approval yet received NCT01989754 INVOKANA 3 Regulatory approval yet received NCT00488631 SIMPONI 3 Trial ongoing/completed <18 month ago NCT00265122 STELARA 1 Regulatory approval yet received NCT00771667 STELARA 2 Regulatory approval yet received NCT01090427 STELARA 1 Trial ongoing/completed <18 month ago regulatory approval yet received NCT01369329 STELARA 1 Regulatory approval yet received NCT01369342 STELARA 1 Regulatory approval yet received NCT02407236 STELARA 1 Trial ongoing/completed <18 month ago NCT01343277 YONDELIS 1 Trial ongoing/completed <18 month ago NCT00887198 ZYTIGA 5 Trial ongoing/completed <18 month ago NCT01591122 ZYTIGA 1 Trial ongoing/completed <18 month ago NCT01715285 ZYTIGA 6 Trial ongoing/completed <18 month ago Total: 18 Total: 36 *Last update: January 1, 2024 Note: Inquiries trial sponsored one YODA Projects current partnering Data Partners included either lists. Side navigation Data Requests Inquiries CSR Summaries website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Login Login via CAS: Username Email Address Password Remember Connect [openid_connect_generic_login_button] Side navigation website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Approved Data Requests YODA Project review data request ensure proposal ha scientific merit, 1) scientific purpose clearly described; 2) data requested used create materially enhance generalizable scientific and/or medical knowledge inform science public health; 3) proposed research reasonably addressed using requested data. Click one following Data Partners view approved data requests: Side navigation Request Data website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Featured Articles Hopkins AM, Modi ND, Abuhelwa AY, Kichenadasse G, Kuderer NM, Lyman GH, Wiese MD, McKinnon RA, Rockhold FW, Mann A, Rowland A, Sorich MJ. Heterogeneity Utility Pharmaceutical Company Sharing Individual-Participant Data Packages. JAMA Oncol. 2023 Dec 1;9(12):1621-1626. doi: 10.1001/jamaoncol.2023.3996. PMID: 37796495; PMCID: PMC10557028. Almansour SA, Alqudah MAY, Abuhelwa Z, Al-Shamsi HO, Semreen MH, Bustanji Y, Soare NC, McKinnon RA, Sorich MJ, Hopkins AM, Abuhelwa AY. Association proton pump inhibitor use survival adverse effect outcome patient multiple myeloma: pooled analysis three clinical trials. Sci Rep. 2024 Jan 5;14(1):591. doi: 10.1038/s41598-023-48640-1. PMID: 38182614; PMCID: PMC10770405. Chen R, Tie Y, Huang Y, Zhang X, Zeng Z, Chen M, Li L, Zhang S. Rapidly achieving clinical remission ulcerative colitis indicates better endoscopic histological outcomes. United European Gastroenterol J. 2023 Dec 30. doi: 10.1002/ueg2.12515. Epub ahead print. PMID: 38159047. Chekroud AM, Hawrilenko M, Loho H, Bondar J, Gueorguieva R, Hasan A, Kambeitz J, Corlett PR, Koutsouleris N, Krumholz HM, Krystal JH, Paulus M. Illusory generalizability clinical prediction models. Science. 2024 Jan 12;383(6679):164-167. doi: 10.1126/science.adg8538. Epub 2024 Jan 11. PMID: 38207039. Harton J, Segal B, Mamtani R, Mitra N, Hubbard RA. Combining real-world randomized control trial data using data-adaptive weighting via on-trial score. Statistics Biopharmaceutical Research. 2022;15(2):40820. doi:10.1080/19466315.2022.2071982 Fukuokaya W, Mori K, Yanagisawa T, Akazawa K, Shimomura T, Kimura T. Association concomitant proton pump inhibitor use survival patient metastatic prostate cancer receiving abiraterone acetate: post-hoc analysis pooled data three randomized controlled trials. Prostate Cancer Prostatic Dis. 2023 Jul 18. doi: 10.1038/s41391-023-00695-x. Epub ahead print. PMID: 37464102. Ruzich E, Ritchie J, Ginchereau Sowell F, et al. powerful partnership: researcher patient working together develop patient-facing summary clinical trial outcome data. Journal American Medical Informatics Association : JAMIA. 2023 Jun:ocad099. DOI: 10.1093/jamia/ocad099. PMID: 37341698. Samara MT, Levine SZ, Leucht S. Linkage Young Mania Rating Scale Clinical Global Impression Scale Enhance Utility Clinical Practice Research Trials. Pharmacopsychiatry. 2023 Jan;56(1):18-24. doi: 10.1055/a-1841-6672. Epub 2022 Jul 27. PMID: 35896419. Nikolin S, Rodgers A, Schwaab A, Bahji A, Zarate C Jr, Vazquez G, Loo C. Ketamine treatment major depression: systematic review meta-analysis. EClinicalMedicine. 2023 Aug 3;62:102127. doi: 10.1016/j.eclinm.2023.102127. PMID: 37593223; PMCID: PMC10430179. Chen R, Li L, Tie Y, Chen M, Zhang S. Trajectory fecal lactoferrin predicting prognosis ulcerative colitis. Precis Clin Med. 2023 Sep 5;6(3):pbad022. doi: 10.1093/pcmedi/pbad022. PMID: 38025971; PMCID: PMC10680133. Roy S, Sun Y, Wallis CJD, Kishan AU, Morgan SC, Spratt DE, Malone S, Saad F. Prognostic Role Dynamic Changes Serological Markers Metastatic Hormone Nave Prostate Cancer. Cancers (Basel). 2023 Sep 2;15(17):4392. doi: 10.3390/cancers15174392. PMID: 37686668; PMCID: PMC10486494. Bittner N, Funk CSM, Schmidt A, Bermpohl F, Brandl EJ, Algharably EEA, Kreutz R, Riemer TG. Psychiatric Adverse Events Acetylcholinesterase Inhibitors Alzheimers Disease Parkinsons Dementia: Systematic Review Meta-Analysis. Drugs Aging. 2023 Nov;40(11):953-964. doi: 10.1007/s40266-023-01065-x. Epub 2023 Sep 8. PMID: 37682445; PMCID: PMC10600312. Mathai DS, Nayak SM, Yaden DB, Garcia-Romeu A. Reconsidering dissociation predictor antidepressant efficacy esketamine. Psychopharmacology (Berl). 2023 Apr;240(4):827-836. doi: 10.1007/s00213-023-06324-8. Epub 2023 Feb 2. PMID: 36729145. Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Predicting Endoscopic Improvement Ulcerative Colitis Using Ulcerative Colitis Severity Index. Inflamm Bowel Dis. 2023 Apr 28:izad074. doi: 10.1093/ibd/izad074. Epub ahead print. PMID: 37116893. Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Delayed Ustekinumab Responders Ulcerative Colitis Greater Inflammatory Burden Similar Outcomes Early Responders. Clin Gastroenterol Hepatol. 2023 Jun 29:S1542-3565(23)00496-2. doi: 10.1016/j.cgh.2023.06.011. Epub ahead print. PMID: 37391059. Doi Y, Hamano T, Yamaguchi S, Sakaguchi Y, Kaimori JY, Isaka Y. Mediators canagliflozin renoprotection vary depending patient characteristics: Insights CREDENCE trial. Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15191. Epub ahead print. PMID: 37385955. Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool Individualize Effect Canagliflozin Cardiovascular Risk Type 2 Diabetes. Diabetes Care. 2022 Apr 1;45(4):965-974. doi: 10.2337/dc21-1765. PMID: 35120199; PMCID: PMC9016734. dAngremont E, Begemann MJH, van Laar T, Sommer IEC. Cholinesterase Inhibitors Treatment Psychotic Symptoms Alzheimer Disease Parkinson Disease: Meta-analysis. JAMA Neurol. 2023 Aug 1;80(8):813-823. doi: 10.1001/jamaneurol.2023.1835. PMID: 37358841; PMCID: PMC10294019. Chen R, Tie Y, Zhang X, Li L, Chen M, Zhang S. Fecal lactoferrin early predicts long-term outcome ulcerative colitis: post-hoc analysis UNIFI PURSUIT trials. United European Gastroenterol J. 2023 Jun 23. doi: 10.1002/ueg2.12431. Epub ahead print. PMID: 37350349. Hock RS, Feeney A, Iovieno N, et al. Rapidity symptom improvement intranasal esketamine major depressive disorder: systematic review meta-analysis.J Clin Psychiatry. 2023;84(1):21r14086. Borisov AN, Kutz A, Christ ER, Heim MH, Ebrahimi F. Canagliflozin Metabolic Associated Fatty Liver Disease Patients Diabetes Mellitus: New Insights CANVAS. J Clin Endocrinol Metab. 2023 May 7:dgad249. doi: 10.1210/clinem/dgad249. Epub ahead print. PMID: 37149821. Wong, E.C.L., Merat, S., Monaco, C.et al.Comparative Efficacy Infliximab Versus Tofacitinib Inducing Remission Biologic Naive Ulcerative Colitis: Propensity Matched Study.Dig Dis Sci68, 26352646 (2023). https://doi.org/10.1007/s10620-023-07956-8 Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, Rathkopf DE, Saad F, Ryan CJ, Small EJ, Kelly WK. External Validation Prognostic Model Overall Survival Men Chemotherapy-Nave Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Apr 11:JCO2202661. doi: 10.1200/JCO.22.02661. Epub ahead print. PMID: 37040594. Burschinski A, Schneider-Thoma J, Chiocchia V, Schestag K, Wang D, Siafis S, Bighelli I, Wu H, Hansen WP, Priller J, Davis JM, Salanti G, Leucht S. Metabolic side effect person schizophrenia mid- long-term treatment antipsychotics: network meta-analysis randomized controlled trials. World Psychiatry. 2023 Feb;22(1):116-128. doi: 10.1002/wps.21036. PMID: 36640396; PMCID: PMC9840505. Roughley, M,Mena, C,Howard, R,Reeves, S,Bertrand, J.Guiding safer risperidone prescribing Alzheimers disease therapeutic drug monitoring.Br J Clin Pharmacol.2023;1-6. doi:10.1111/bcp.15692 Loiseau, N., Trichelair, P., He, M.et al.External control arm analysis: evaluation propensity score approaches, G-computation, doubly debiased machine learning.BMC Med Res Methodol22, 335 (2022). https://doi.org/10.1186/s12874-022-01799-z VeronikiAA,AshoorHM,RiosP, et alComparative safety efficacy cognitive enhancer Alzheimers dementia: systematic review individual patient data network meta-analysisBMJ Open2022;12:e053012.doi:10.1136/bmjopen-2021-053012 Hopkins, S.C., Ogirala, A., Zeni, C.et al.Depicting Risperidone Safety Profiles Clinical Trials Across Different Diagnoses Using Dopamine D2-Based Pharmacological Class Effect Query Defined FAERS.Clin Drug Investig42, 11131121 (2022). https://doi.org/10.1007/s40261-022-01218-7 S. Roy, Y. Sun, S.C. Morgan et al., Effect Prior Local Therapy Response First-line Androgen Receptor Axis Targeted Therapy Metastatic Castrate-resistant Prostate Cancer: Secondary Analysis COU-AA-302 Trial, Eur Urol (2023), https://doi.org/10.1016/j. eururo.2023.02.017 Brandt, L., et al. (2023). Predicting psychotic relapse following randomised discontinuation paliperidone individual schizophrenia schizoaffective disorder: individual participant data analysis. Lancet Psychiatry 10(3): 184-196. Siebert M, Gaba J, Renault A, Laviolle B, Locher C, Moher D, Naudet F. Data-sharing re-analysis main study assessed European Medicines Agency-a cross-sectional study European Public Assessment Reports. BMC Med. 2022 May 20;20(1):177. doi: 10.1186/s12916-022-02377-2. PMID: 35590360; PMCID: PMC9119701. Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Higher Postinduction Infliximab Concentrations Associated Improved Clinical Outcomes Fistulizing Crohns Disease: ACCENT-II Post Hoc Analysis. J Gastroenterol. 2021 May 1;116(5):1007-1014. doi: 10.14309/ajg.0000000000001111. PMID: 33929379; PMCID: PMC8095681. Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Higher Postinduction Infliximab Concentrations Associated Improved Clinical Outcomes Fistulizing Crohns Disease: ACCENT-II Post Hoc Analysis. J Gastroenterol. 2021 May 1;116(5):1007-1014. doi: 10.14309/ajg.0000000000001111. PMID: 33929379; PMCID: PMC8095681. Dulai PS, Jairath V, Narula N, Wong E, Kochhar GS, Colombel JF, Sandborn WJ. Microsimulation Model Determine Cost-Effectiveness Treat-to-Target Strategies Crohns Disease. J Gastroenterol. 2021 Aug 1;116(8):1709-1719. doi: 10.14309/ajg.0000000000001263. PMID: 34587127; PMCID: PMC8481677. GouraudH,WallachJD,BoussageonR, et alVibration effect 16 000 pooled analysis individual participant data 12 randomised controlled trial comparing canagliflozin placebo type 2 diabetes mellitus: multiverse analysis BMJ Medicine2022;1:e000154.doi:10.1136/bmjmed-2022-000154 McCutcheon RA, Pillinger T, Efthimiou O, Maslej M, Mulsant BH, Young AH, Cipriani A, Howes OD. Reappraising variability effect antipsychotic medication schizophrenia: meta-analysis. World Psychiatry. 2022 Jun;21(2):287-294. doi: 10.1002/wps.20977. PMID: 35524614; PMCID: PMC9077611. Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Predictors Placebo Induction Response Remission Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Aug 24:S1542-3565(22)00811-4. doi: 10.1016/j.cgh.2022.08.015. Epub ahead print. PMID: 36029969. KerschbaumerA,RivaiZI,SmolenJS, et alImpact pre-existing background therapy placebo response randomised controlled clinical trial rheumatoid arthritis.Annals Rheumatic DiseasesPublished Online First:20 June 2022.doi:10.1136/annrheumdis-2021-221807 Zou X, Huang Q, Luo Y, Ren Q, Han X, Zhou X, Ji L. efficacy canagliflozin diabetes subgroup stratified data-driven clustering supervised machine learning method: post hoc analysis canagliflozin clinical trial data. Diabetologia. 2022 Jul 8. doi: 10.1007/s00125-022-05748-9. Epub ahead print. PMID: 35802168. Narula, Neeraj MD, MPH, FRCPC1; Wong, Emily C.L. BHSc1; Dulai, Parambir S. MD2; Marshall, John K. MD, MSc, FRCPC1; Jairath, Vipul MD, PhD3; Reinisch, Walter MD, PhD4Comparative Effectiveness Biologics Endoscopic Healing Ileum Colon Crohns Disease, American Journal Gastroenterology: April 15, 2022 Volume Issue 10.14309/ajg.0000000000001795 doi: 10.14309/ajg.0000000000001795 Agrawal, Manasi & Petralia, Francesca & Tepler, Adam & Durbin, Laura & Reinisch, Walter & Colombel, Jean-Frederic & Shah, Shailja. (2022). Gender-Based Differences Response Tumor Necrosis Factor Inhibitor Therapies Ulcerative Colitis: Individual Participant Data Meta-Analyses Clinical Trials. Inflammatory Bowel Diseases. 10.1093/ibd/izac067. Mishriky BM, Cummings DM, Powell JR. Cardiovascular benefit GLP-1RA SGLT-2i woman type 2 diabetes. Prim Care Diabetes. 2022 Apr 5:S1751-9918(22)00073-0. doi: 10.1016/j.pcd.2022.03.012. Epub ahead print. PMID: 35396200. Khan FA, Stewart I, Moss S, Fabbri L, Robinson KA, Johnson SR, Jenkins RG. Three-Month FVC Change: Trial Endpoint IPF Based Individual Participant Data Meta-Analysis. J Respir Crit Care Med. 2022 Jan 12. doi: 10.1164/rccm.202109-2091OC. Epub ahead print. PMID: 35020580. Kearns B, Stevenson MD, Triantafyllopoulos K, Manca A. Comparing current emerging practice model extrapolation survival data: simulation study case-study. BMC Med Res Methodol. 2021 Nov 27;21(1):263. doi: 10.1186/s12874-021-01460-1. PMID: 34837957; PMCID: PMC8627632. Narula N, Wong ECL, Colombel JF, Sandborn WJ, Ferrante M, Marshall JK, Reinisch W, Dulai PS. Early Reduction MM-SES-CD Score Initiation Biologic Therapy Highly Specific One-Year Endoscopic Remission Moderate Severe Crohns Disease. J Crohns Colitis. 2021 Oct 19:jjab183. doi: 10.1093/ecco-jcc/jjab183. Epub ahead print. PMID: 34664635. Narula N, Pray C, Wong ECL, Colombel JF, Marshall JK, Daperno M, Reinisch W, Dulai PS. Categorizing Endoscopic Severity Crohns Disease Using Modified Multiplier SES-CD (MM-SES-CD). J Crohns Colitis. 2022 Feb 3:jjac018. doi: 10.1093/ecco-jcc/jjac018. Epub ahead print. PMID: 35134140. Mellem MS, Kollada M, Tiller J, Lauritzen T. Explainable AI enables clinical trial patient selection retrospectively improve treatment effect schizophrenia. BMC Med Inform Decis Mak. 2021 May 20;21(1):162. doi: 10.1186/s12911-021-01510-0. PMID: 34016112; PMCID: PMC8135147. Carretero-Gonzlez A, Lora D, Manneh R, Lorente D, Castellano D, de Velasco G. Combination statin/vitamin metastatic castration-resistant prostate cancer (CRPC): post hoc analysis two randomized clinical trials. Clin Transl Oncol. 2020 Nov;22(11):2126-2129. doi: 10.1007/s12094-020-02334-6. Epub 2020 Mar 20. PMID: 32198642. Wang R, Dasgupta A, Ward MM. Predicting Probability Response Tumor Necrosis Factor Inhibitors Individual Patients Ankylosing Spondylitis.JAMA Netw Open.2022;5(3):e222312. doi:10.1001/jamanetworkopen.2022.2312 Wang J, Arroyo-Suarez R, Dasari S, Sekaran K, Tse W. Early versus late response daratumumab-based triplet therapy patient multiple myeloma: pooled analysis trial POLLUX, CASTOR MAIA. Leuk Lymphoma. 2022 Feb 10:1-9. doi: 10.1080/10428194.2022.2038376. Epub ahead print. PMID: 35142582. Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Resolution dominant patient-reported outcome end induction predicts clinical endoscopic remission Crohns disease. Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16805. Epub ahead print. PMID: 35166396. Brandt L, Schneider-Thoma J, Siafis S, Efthimiou O, Bermpohl F, Loncar L, Neumann K, Hasan A, Heinz A, Leucht S, Gutwinski S. Adverse event antipsychotic discontinuation: individual participant data meta-analysis. Lancet Psychiatry. 2022 Mar;9(3):232-242. doi: 10.1016/S2215-0366(22)00014-1. PMID: 35183280. Sim R, Chong CW, Loganadan NK, et al. Comparative effectiveness cardiovascular, renal safety outcome second-line antidiabetic drug use people type 2 diabetes: systematic review network meta-analysis randomised controlled trials. Diabet Med. 2021 Dec 28:e14780. doi: 10.1111/dme.14780. Epub ahead print. PMID: 34962662. Beelen EMJ, Nieboer D, Arkenbosch JHC, et al. Risk Prediction Comparative Efficacy Anti-TNF v Thiopurines, Preventing Postoperative Recurrence Crohns Disease: Pooled Analysis 6 Trials. Clin Gastroenterol Hepatol. 2021 Oct 20:S1542-3565(21)01134-4. doi: 10.1016/j.cgh.2021.10.021. Epub ahead print. PMID: 34687970. Ben-Horin S, Novack L, Mao R, et al. Efficacy Biologic Drugs Short-Duration Versus Long-Duration Inflammatory Bowel Disease: Systematic Review Individual-Patient Data Meta-Analysis Randomized Controlled Trials. Gastroenterology. 2022 Feb;162(2):482-494. doi: 10.1053/j.gastro.2021.10.037. Epub 2021 Oct 29. PMID: 34757139. Zhu Y, Centorrino F, Jackson JW, Fitzmaurice GM, Valeri L.Epidemiology. 2021 Jan;32(1):120-130. doi: 10.1097/EDE.0000000000001269. PMID: 33181564. Narula N, Wong ECL, Marshall JK, Colombel JF, Dulai PS, Reinisch W.Clin Gastroenterol Hepatol. 2021 Jul 28:S1542-3565(21)00820-X. doi: 10.1016/j.cgh.2021.07.038. Epub ahead print. PMID: 34329776. Lorente D, Llacer C, Lozano R, et al.European Urology. 2021. doi: https://doi.org/10.1016/j.eururo.2021.07.014 Schoretsanitis G, Kane JM, Correll CU, Rubio JM.Schizophrenia Bulletin.2021, sbab091. https://doi.org/10.1093/schbul/sbab091 Hieronymus F, Klbk P, Correll CU, stergaard SD.npj Schizophrenia. 2021;7(1):41. Hodkinson A, Heneghan C, Mahtani KR, Kontopantelis E, Panagioti M.BMC Med. 2021 Aug 25;19(1):195. doi: 10.1186/s12916-021-02062-w. PMID: 34429113; PMCID: PMC8386072. Pan J, Wang J, Wei Y, Zhang T, Zhang S, Ye D, Zhu Y.Cancer Med. 2021 Aug 20. doi: 10.1002/cam4.4205. Epub ahead print. PMID: 34414685. Narula N, Aruljothy A, Wong ECL, Homenauth R, Alshahrani AA, Marshall JK, Reinisch W.United European Gastroenterol J.2021 Jun;9(5):581-589. doi: 10.1002/ueg2.12094. Epub 2021 Jun 2. PMID: 34077627; PMCID: PMC8259251. Wang L, Paller C, Hong H, Rosman L, De Felice A, Brawley O, Alexander GC.J Natl Cancer Inst.2021 Apr 8:djab071. doi: 10.1093/jnci/djab071. Epub ahead print. PMID: 33830214. Ternov KK, Nolse AB, Bratt O, Fode M, Lindberg H, Kistorp C, Palapattu G, Klausen TW, Snksen J, stergren PB.Prostate Cancer Prostatic Dis. 2021 Apr 5. doi: 10.1038/s41391-021-00359-8. Epub ahead print. PMID: 33820951. Wang J, Park C, Arroyo-Suarez R.Leuk Lymphoma.2021 Apr 9:1-8. doi: 10.1080/10428194.2021.1910687. Epub ahead print. PMID: 33836624. Narula N, Wong ECL, Dulai P, Sengupta NK, Marshall JK, Colombel JF,Reinisch W.Clin Gastroenterol Hepatol. 2021 Apr 7. doi: https://doi.org/10.1016/j.cgh.2021.04.006. Epub ahead print. Narula N, Wong ECL, Colombel JF, Sandborn WJ, Marshall JK, Daperno M, Reinisch W, Dulai P.Gut. 2021 Mar 25:gutjnl-2020-323799. doi: 10.1136/gutjnl-2020-323799. Epub ahead print. PMID: 33766910. Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W.J Crohns Colitis. 2021 Mar 6:jjab045. doi: 10.1093/ecco-jcc/jjab045. Epub ahead print. PMID: 33693522. Fraenkel L, Wei Z, Ramsey C, Wiedmeyer C, Michaud K, Neogi T, Nowell WB, Venkatachalam S, Broniatowski DA.PLoS One. 2021 Jan 29;16(1):e0245598. doi: 10.1371/journal.pone.0245598. PMID: 33513209. Mishriky BM, Okunrintemi V, Jain S, Sewell KA, Powell JR, Cummings DM.Diabetes Metab. 2020 May 18:S1262-3636(20)30076-8. doi: 10.1016/j.diabet.2020.05.002. Epub ahead print. PMID: 32439471. Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS.Am. J. Gastroenterol.2020December 18. Publish Ahead Print. Marques ML, Ramiro S, Machado PM, van der Heijde D, van Gaalen FA.RMD Open. 2020 Dec;6(3):e001391. doi: 10.1136/rmdopen-2020-001391. PMID: 33310864. Lu TX, Dapas M, Lin E, Peters T, Sakuraba A.Gut. 2020 Dec 17:gutjnl-2020-321609. doi: 10.1136/gutjnl-2020-321609. Epub ahead print. PMID: 33334900. Rabinowitz J, Young RC, Yavorsky C, Williams JBW, Sedway J, Marino P, Matteo C, Mahableshwarkar A, Kott A, Hefting N, Engler J, Brady C. Consistency check improve measurement Young Mania Rating Scale (YMRS). J Affect Disord. 2024 Jan 15;345:24-31. doi: 10.1016/j.jad.2023.10.098. Epub 2023 Oct 20. PMID: 37865349. Wong ECL, Marshall JK, Reinisch W, Narula N.Inflamm Bowel Dis. 2020 Aug 19; izaa214.doi: 10.1093/ibd/izaa214.Online ahead print. Hanlon P, Butterly E, Lewsey J, Siebert S, Mair FS, McAllister DA.BMC Med. 2020 Oct 22;18(1):309. doi: 10.1186/s12916-020-01752-1. PMID: 33087107; PMCID: PMC7579922. Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W.J Crohns Colitis.2020 Sep 15:jjaa189. doi: 10.1093/ecco-jcc/jjaa189. Epub ahead print. PMID: 32931556. Ferreira RJO, Welsing PMJ, Jacobs JWG, Gossec L, Ndosi M, Machado PM, van der Heijde D, Da Silva JAP.Ann Rheum Dis.2020 Oct 6. doi: 10.1136/annrheumdis-2020-217171. Epub ahead print. Rubio JM, Schoretsanitis G, John M, Tiihonen J, Taipale H, Guinart D, Malhotra AK, Correll CU, Kane JM.Lancet Psychiatry. 2020;7(9):749-761. doi:10.1016/S2215-0366(20)30264-9 Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. J Gastroenterol. 2020;115(8):1236-1245. doi:10.14309/ajg.0000000000000617 Faleck DM, Shmidt E, Huang R, Katta LG, Narula N, Pinotti R, Suarez-Farinas M, Colombel JF.Clin Gastroenterol Hepatol. [Epub ahead print, 2020 Jun 19]. 2020;S1542-3565(20)30847-8. doi:10.1016/j.cgh.2020.06.036 Hanlon P, Hannigan L, Rodriguez-Perez J, Fischbacher C, Welton NJ, Dias S, Mair FS, Guthrie B, Wild S, McAllister DA.BMC Med.2019 Nov 12;17(1):201. doi: 10.1186/s12916-019-1427-1. Cheng D, Cushing KC, Cai T, Ananthakrishnan AN.Clin Gastroenterol Hepatol. 2020 May 1;pii: S1542-3565(20)30615-7. doi: 10.1016/j.cgh.2020.04.070. [Epub ahead print] Spertus J, Horvitz-Lennon M, Normand S.Med Decis Making.2019 Aug 2:272989X19856884.[Epub ahead print] doi:10.1177/0272989X19856884 Christian KE, Russman KM, Rajan DP, Barr EA, Cross RK.Inflamm Bowel Dis. 2019 Jul 2. pii: izz133. doi: 10.1093/ibd/izz133. [Epub ahead print] Schneider-Thoma J,Efthimiou O,Bighelli I,Drries C,Huhn M,Krause M,Reichelt L,Rder H,Furukawa TA, Davis JM,Leucht S.Lancet Psychiatry. 2019 July. 0(0). doi:10.1016/S2215-0366(19)30223-8. Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V.Clin Gastroenterol Hepatol.2019 May; pii:S1542-3565(19)30529-4. doi: 10.1016/j.cgh.2019.05.019. [Epub ahead print] Waljee AK, Wallace BI, Cohen-Mekelburg S, Liu Y, Liu B, Sauder K, Stidham RW, Zhu J, Higgins PDR.JAMA Netw Open2019 May;2(5):e193721. doi: 10.1001/jamanetworkopen.2019.3721. Teply BA, Qiu F, Antonarakis ES, Carducci MA, Denmeade SR.Prostate. 2019 Jun;79(8):929-933. doi: 10.1002/pros.23798. Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, Frchet-Jachym M, Robert J, Veziris N, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Schnemann HJ, Lienhardt C.Emerg Infect Dis. 2019 May;25(5):936-943. doi: 10.3201/eid2505.181823. Waljee AK, Sauder K, Zhang Y, Zhu J, Higgins PDR.Clin Gastroenterol Hepatol. 2018 Mar;16(3):449-451. doi: 10.1016/j.cgh.2017.08.021. Yiu ZZN, Mason KJ, Barker JNWN, Hampton PJ, McElhone K, Smith CH, Warren RB, Griffiths CEM, Lunt M, Burden AD; BADBIR Study Group.Br J Dermatol. [Epub ahead print 1 Mar 2019]. doi: 10.1111/bjd.17849. Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P.Eur Urol Oncol. 2019. doi: 10.1016/j. euo.2019.01.009 Martin LJ, Alibhai SMH, Komisarenko M, Timilshina N, Finelli A.Can Urol Assoc J. [Epub ahead print 5 Nov 2018]. doi: 10.5489/cuaj.5586. Kumagai F, Suzuki T, Fleischhacker WW, Yasui-Furukori N, Mimura M, Uchida H.J Clin Psychiatry. 2018 Dec 4;80(1). pii: 18m12144. doi: 10.4088/JCP.18m12144. Kubo K, Fleischhacker WW, Suzuki T, Yasui-Furukori N, Mimura M, Uchida H.Acta Psychiatr Scand.[Epub ahead print 9 Sep 2018]. doi: 10.1111/acps.12960. Narula N, Alshahrani AA, Yuan Y, Reinisch W, Colombel JF.Clin Gastroenterol Hepatol.[Epub ahead print 15 Jun 2018] doi: 10.1016/j.cgh.2018.06.015. Schneider-Thoma J, Efthimiou O, Huhn M, Krause M, Reichelt L, Rder H, Davis JM, Salanti G, Leucht S.Lancet Psychiatry.2018;5(8):653-663. doi: 10.1016/S2215-0366. Wilcox MA, Savitz AJ, Addington AM, Gray GS, Guinan EC, Jackson JW, Lehner T, Normand SL, Ranu H, Senthil G, Spertus J, Valeri L, Ross JS.NPJ Schizophr.2018;4(1):14. doi: 10.1038/s41537-018-0055-7. Spertus J, Horvitz-Lennon M, Abing H, Normand S.NPJ Schizophr.[Epub ahead print 27 June 2018] doi: 10.1038/s41537-018-0053-9 Zou X, Zhu Y, Jackson JW, Bellavia A, Fitzmaurice GM, Centorrino F, Valeri L.NPJ Schizophr.[Epub ahead print 27 June 2018] doi: 10.1038/s41537-018-0054-8 Singh S, Proudfoot J, Xu R, Sandborn WJ.Inflamm Bowel Dis.[Epub ahead print 18 May 2018] doi: 10.1093/ibd/izy135 Singh S, Proudfoot J, Xu R, Sandborn WJ.Am J Gastroenterol. 2018;113(6):883-889. doi: 10.1038/s41395-018-0104-x Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ.Am J Gastroenterol. [Epub ahead print 21 June 2018] doi: 10.1038/s41395-018-0144-2 Mbuagbaw L.Appendix inA 2016 review available evidence use bedaquiline treatment multidrug-resistant tuberculosis. Geneva; 2017. reference number: WHO/HTM/TB/2017.01 Wang R, Dasgupta A, Ward MM.J Rheumatol. [Epub ahead print 15 January 2018] doi: 10.3899/jrheum.170224 Gay HC, Baldridge AS, Huffman MD.JAMA Cardiology. [Epub ahead print 18 October 2017] doi: 10.1001/jamacardio.2017.3808 Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, Walton M, Harden M, Ho P, Woolacott N, Bojke L.Health Technology Assessment. 2017;21(56). Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, Helfand M.Ann Intern Med. 2013;158:890-902. Mospan GA, Wargo KA.J Board Fam Med. 2016;29:654-662. Laurie AL, Chen Y, Chou R, Fu R.Spine. 2016;41:E1115-1123. Noshchenko A, Lindley EM, Burger EL, Cain CM, Patel, VV.Spine. 2016;41:9-17. Simmonds MC, Brown JV, Heirs MK, Higgins JP, Mannion RJ, Rodgers MA, Stewart LA.Ann Intern Med. 2013;158:877-889. VeronikiAA,StrausSE,AshoorHM, et al Comparative safety effectiveness cognitive enhancer Alzheimers dementia: protocol systematic review individual patient data network meta-analysis BMJ Open2016;6:e010251.doi:10.1136/bmjopen-2015-010251 website designed YODA Project Menu Policies & Procedures Data Partners Johnson & Johnson Medtronic Conferences Request Request Data Metrics Data Requests Inquiries CSR Summaries Site Map Table Contents Pages Article Features Clinical TrialsData Requests website designed